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Human African trypanosomiasis (sleeping sickness), caused by the protozoan parasite 
Trypanosoma brucei, is fatal if untreated. Current drugs are cumbersome to deliver and severely 
toxic. New antitrypanosomals are greatly needed. The molecular chaperone Hsp90 is conserved 
and highly expressed in eukaryotes, and essential for several regulatory cell pathways. Hsp90 
inhibitors were investigated for anti-trypanosomal activity. Geldanamycin, radicicol, and NVP-
AUY922 had nanomolar potency against bloodstream form T. brucei in vitro; CUDC-305 and 
novobiocin had micromolar activity.  Structure–activity studies of geldanamycin analogs found 
17-AAG and 17-DMAG were most selective against T. brucei compared to mammalian cells.  
Both oral and parenteral 17-DMAG cured mice of a normally lethal infection of T. brucei.  17-
AAG treatment sensitized trypanosomes to heat shock and caused severe cell cycle disruption. 
Cytokinesis and kinetoplast replication were particularly affected. RNAi of trypanosome Hsp90s, 
HSP83 and Tb427tmp.02.0250 (putative mitochondrial Hsp90), caused growth defects. Loss of 
HSP83 inhibited cytokinesis, and loss of Tb427tmp.02.0250 disrupted kinetoplast replication, 
similar effects to those seen with 17-AAG. These promising results support the use of inhibitors 
to study Hsp90 function in trypanosomes and to expand current clinical development of Hsp90 
inhibitors to include T. brucei.  Correct dosing can be the critical difference between efficacy and 
failure, not only in the total dose administered but also in the shape of the drug concentration-
time curve produced. A hollow-fiber cartridge model was developed to study pharmacokinetic-
pharmacodynamic relationships of antitrypanosomals. Contrasting pharmacokinetic profiles, with 
artificial kinetics favoring either high peak concentrations or sustained drug levels, were delivered 
to parasites. Simply changing the shape of exposure significantly shifted the dose-response curve 
of 17-AAG, affecting potency and efficacy. Hsp90 inhibitors from three chemical scaffolds were 
concentration-driven: significantly more efficacious applied as short-lived high peaks. For 
optimal efficacy, ideal pharmacokinetic properties and dosing regimens of Hsp90 inhibitors as 
antitrypanosomals will produce high peaks in vivo. The PK-PD system was also used to study 
four clinically used and two candidate antitrypanosomals. In vitro PK-PD methodology is 
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Trypanosoma brucei is a protozoan parasite and causes human African trypanosomiasis (HAT, 
sleeping sickness). Passed by the bite of the tsetse fly, the parasite is extracellular and exhibits 
frequent antigenic variation of its surface glycoprotein coat, allowing evasion of the immune 
system (1). In mammals trypanosomes differentiate into the bloodstream form lifecycle stage, 
which divides rapidly by mitosis and survives by glycolysis. The parasites live in the blood, lymph, 
and tissues, and in late-stage disease move in to the CNS leading to devastating neurological 
symptoms and death (2). Subspecies T. b. gambiense is predominantly found in west and central 
Africa and typically causes an infection that takes several years to progress, whereas T. b. 
rhodesiense is located in east Africa and causes an acute and aggressive infection which leads to 
death within a few months if untreated (2).  
 
There are currently five drugs used clinically to treat HAT (Fig. 1). Suramin was one of the 
very first antitrypanosomals, developed in the Bayer dye company in the early 1900s (3). It 
unfortunately has limited blood-brain barrier permeability, and is thus only effective against early-
stage infection. Similarly pentamidine, introduced in the 1940s, is very effective against peripheral 
infection but inactive against late-stage disease (4). Originating from the work of Paul Ehrlich, 
organic arsenicals have been used for over a century to treat the CNS disease. The trivalent 
arsenical melarsoprol, introduced in the late 1940s, remains in use today as the only option for 
late-stage rhodesiense infection (5). Gambiense CNS disease is now predominantly treated with 
difluoromethylornithine (DFMO) in combination with nifurtimox. DFMO was repurposed from 
the oncology field as an antitrypanosomal in the 1980s (6). Although effective against 
trypanosomes, these drugs all have severe toxicities. Melarsoprol is particularly toxic, frequently 
causing a reactive encephalopathy that leads to death in 2-10% of treated patients (1). Along with 
the toxicities, the current antitrypanosomals have lengthy and cumbersome treatment regimens, 
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difficult to administer in the rural setting of this infection. There is unmet medical need for 
treatment of this deadly disease.    
 
Figure 1. Chemical structures of clinically used antitrypanosomals 
 
The repurposing of DFMO, which inhibits ornithine decarboxylase, illustrates that as a 
eukaryote T. brucei contains homologues of mammalian proteins and is thus susceptible to many 
compounds effective against mammalian cells. The converse is also true, and in fact suramin and 
melarsoprol are cytotoxic against cancer cells in vitro and have been tested in clinical oncology 
trials (7,8). Despite shared cytotoxicity, each of these compounds has a selectivity index for 
trypanosomes over mammalian cells. Preferential drug uptake in the parasite, divergent enzyme 
structure and regulation, and differential downstream consequences of compound action can all 
produce selective toxicity. Screening and repurposing oncology drugs is thus an effective drug 
development strategy for trypanosomes, as validated by the history of DFMO. This dissertation 
describes the investigation of heat shock protein 90 (Hsp90) inhibitors against trypanosomes, the 
molecular consequences of trypanosomal Hsp90 inhibition, and a pharmacokinetic-
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pharmacodynamic technique to enhance the development of Hsp90 inhibitors and all 
antitrypanosomals. 
 
Hsp90 is a molecular chaperone found in high abundance in all eukaryotes and bacteria (9). 
Chaperones are important for the correct folding and function of other proteins, and are thus 
essential for protein homeostasis. Hsp90 is a large 90 kDa protein that functions as a dimer and 
has ATPase capacity thought to drive conformational changes (Fig. 2) (10,11). Post-translational 
modifications and co-chaperones play an important role in regulating Hsp90 activity and in 
recruiting specific clients (12). In mammalian cells, Hsp90 clients are involved in multiple cell 
pathways; including receptor mediated signaling cascades, cell cycle regulation, stress responses, 
translation control, and even structural integrity and transport (13). Hsp90 is thus a node at the 
intersection of many essential pathways. 
 
Figure 2. Hsp90 crystal structures  
Crystal structure of full length Hsp90 from E. coli (HtpG) in the open conformation (left, PDB 2IOQ) 
and nucleotide-bound yeast Hsp90 in the closed conformation (right, PDB 2CG9). The N-domain is 
depicted in blue, the M-domain in green and the C-domain in orange. Reprinted from (11) with 
permission from Elsevier (License 3832560660752). 
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The trypanosome homologue of Hsp90 is HSP83. HSP83 is encoded by ten tandem genes in 
T. brucei (14), suggesting high abundance, and has been shown to associate with protein 
phosphatase 5, an important modulatory phosphatase (15). Little is known about the client 
repertoire of HSP83. Although trypanosomes lack homologues of mammalian clients such as 
receptor tyrosine kinases or steroid receptors, some translation and cell cycle regulators are 
conserved. Trypanosomes are ancient divergent eukaryotes and contain many unique cellular 
pathways that may intersect with HSP83 at some level. For example, in trypanosomes gene 
transcription is polycistronic and all mRNAs require a spliced 5’-leader sequence, the processing 
of which is heat-shock sensitive (16). Trypanosome redox stress response relies on the unique 
trypanothione reductase system rather than the glutathione reductase used in mammalian cells 
(17). The trypanosome also contains distinct structural features (Fig. 3)(18). Essential for viability 
is the single flagellum attached along the length of the cell. The flagellum originates from a basal 
body, anchored at one end of the trypanosome. Attached to the basal body is the kinetoplast, a 
unique feature to this family of parasites. The kinetoplast is the genome of the single 
mitochondrion, consisting of a complex network of interlocking DNA plasmids. During the cell 
cycle, the trypanosome has to faithfully replicate and segregate each structure and organelle in an 
ordered process, which requires complex regulation (19).  
 
The first inhibitor of Hsp90 identified was the natural product geldanamycin, which binds in 
the ATP pocket of the N-terminal domain and inhibits Hsp90 ATPase activity (20). This pocket 
is formed by a Bergerat fold, which is also found in histidine kinase, topoisomerase II, and MutL 
proteins (21). Geldanamycin has potent cytotoxic activity against many cancer cell lines (22). 
Selectivity for cancer cells over non-transformed cells arises from an increased need for protein 
homeostasis buffering in the malignant cell due to aberrant mutations, cell stress, and rapid 
proliferation (23). The impressive in vitro results obtained with geldanamycin led to great interest 
in Hsp90 as an anti-cancer target, and development of many inhibitors, both semi-synthetically, 




Figure 3. Sub-structure of T. brucei 
The bloodstream form trypanosome is a slender polarized cell with a single flagellum attached along 
one undulating edge. Microtubules form a corset that maintains the trypanosome structure. The 
flagellum originates from the basal body at one end of the cell. The basal body is also attached to the 
kinetoplast, the densely packed mitochondrial genome. In the trypanosomes the Golgi is a single 
structure, and trypanosomes also have a single mitochondrion and nucleus. Vickerman and Cox, The 
Protozoa, 1967 (25). 
 
 
Figure 4. The original ansamycin, resorcinol, and purine scaffold Hsp90 inhibitors 
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enter the clinic are the benzoquinone ansamycins, derived from geldanamycin, resorcinols (using 
the pharmacophore of radicicol), and purines (based off a rationally designed inhibitor, PU3) 
(Fig. 4)(24). All of these bind in the Bergerat fold. Unfortunately no Hsp90 inhibitor has yet been 
licensed for oncology, as only modest success has been seen in clinical trials (24,26). Alternative 
indications for these inhibitors are of interest, including use as anti-infectives (27).  
 
Development of any drug is enhanced by knowledge of its pharmacokinetic-
pharmacodynamic (PK-PD) relationships, namely the connection between exposure and effect. 
In vivo, drugs are absorbed, distributed, metabolized, and eliminated by the body which produces 
a dynamically changing concentration-time profile (Fig. 5). The total exposure to drug is the area  
 
Figure 5. Typical concentration-time profile of drug in blood after an oral dose 
After an oral dose of drug, the concentration in the blood rises as drug is absorbed from the gut. 
Concentration reaches a maximum, Cmax, when distribution, metabolism, and elimination of the drug 
begin to dominate, and then falls with a certain half-life, t1/2. The total exposure to the drug is 
described by the area under the curve (AUC). A minimum inhibitory concentration (MIC) can be 




under the curve (AUC), and the same AUC can be produced by very differently shaped curves. 
Knowledge of the PK-PD relationships of a drug helps with optimization of physio-chemical 
properties and dosing schedules for pre-clinical and clinical evaluation (28,29). 
 
To assess the potential of repurposing Hsp90 inhibitors against T. brucei, in vitro cytotoxicity 
was determined, in vivo activity in mice was examined, molecular consequences of Hsp90 
inhibitor treatment were compared to genetic knockdown of trypanosome Hsp90s, and in vitro 
pharmacokinetic-pharmacodynamic relationships of Hsp90 inhibitors against trypanosomes were 
investigated.   
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CHAPTER I. Potent antitrypanosomal activities of Hsp90 inhibitors in 
vitro and in vivo 
Published in part in: 
Meyer, K. J., and Shapiro, T. A. (2013) Potent antitrypanosomal activities of heat shock protein 
90 inhibitors in vitro and in vivo. J Infect Dis 208, 489-499 (30) 
 
INTRODUCTION 
African sleeping sickness (human African trypanosomiasis, HAT) is caused by the protozoan 
parasite Trypanosoma brucei (1). T. brucei is transmitted by the tsetse fly and causes endemic disease 
in both livestock (nagana) and humans (HAT) in sub-Saharan Africa.  The parasite propagates 
extracellularly and moves throughout the body, including in late disease into the central nervous 
system.  In humans this infection is fatal unless treated.  Current therapies require repeated 
parenteral dosing and have formidable toxicities, exemplified by the 2-10% lethality caused by the 
commonly used drug melarsoprol.  New anti-trypanosomal drugs are long overdue.   
 
Heat shock protein 90 (Hsp90) is a phylogenetically conserved, abundant, and essential 
molecular chaperone (reviewed in (11,31-35)).  In mammalian cells it functions as a homodimer 
complexed with regulatory co-chaperones.  Hsp90 stabilizes ‘client’ proteins, enabling their 
proper activities.  Over two hundred clients have been identified, with many acting in signal 
transduction pathways, stress responses, and cell cycle regulation (11).  Thus Hsp90 is a critical 
node coordinating many networks necessary for survival.  This combinatorial function and a 
disproportionate dependence on Hsp90 activity in malignant cells have established it as a cancer 
chemotherapy target (33-36).  Dozens of Hsp90 inhibitors have entered the drug development 
pathway, including derivatives of natural products geldanamycin (e.g., 17-N-allylamino-17-
demothoxygeldanamycin (17-AAG), 17-dimethylaminoethylamino-17-demethoxygeldanamycin 
(17-DMAG)) and radicicol, and novel structural scaffolds identified in screens.  17-AAG has 
been in Phase III trials (34).  Geldanamycin treatment leads to proteasomal degradation of Hsp90 
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client proteins, cell cycle arrest, and heat shock response in mammalian cells (37).  Damage to 
multiple proteins and pathways may be the basis for reported synergism between Hsp90 
inhibitors and several chemotherapeutic agents (38).   
 
T. brucei contains a homologue of Hsp90, known as HSP83, for which there are ten tandem 
genes in the genome (14).  Structurally diverse Hsp90 inhibitors, including some already studied 
in humans, were evaluated for their activity against bloodstream form trypanosomes in vitro; 
structure-activity relationships were explored for the geldanamycin scaffold; 17-AAG was tested 
in combination with other drugs; and efficacy of orally dosed 17-DMAG was demonstrated 
against T. brucei infection in mice.   
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MATERIALS AND METHODS  
Cell Culture and Reagents. All studies utilized bloodstream Trypanosoma brucei brucei (MiTat 1.2 
strain 427) maintained continuously in exponential growth (104-106 cells/mL) at 37°C, 5% CO2, 
in phenol red-free HMI-9, 10% fetal bovine serum (Invitrogen) and 10% Serum Plus (SAFC 
Biosciences).  Motile parasites were counted by hemocytometer.  L1210 murine leukemia cells 
(ATCC CCL-219) were maintained in phenol red-free RPMI 1640 (Sigma-Aldrich), 15% fetal 
bovine serum.  Compound stock solutions were aliquoted and stored at -20°C: radicicol (Sigma-
Aldrich), CUDC-305 (ChemieTech), and ansamycins [including geldanamycin, 17-AAG, and 17-
DMAG] (The NCI/DTP Open Chemical Repository, http://dtp.cancer.gov) were all in sterile 
DMSO (Hybri-Max, Sigma-Aldrich).  Final DMSO ≤0.5% had no effect in cytotoxicity assay.   
 
Cytotoxicity Assays and Combination Studies. Cytotoxicity was assayed by colorimetric 96-
well plate acid-phosphatase method (39).  Cells were exposed to various concentrations of 
compound in quadruplicate for 24 h (T. brucei seeded 1x105 cells/mL) or 48 h (L1210 seeded 
7x104 cells/mL), reflecting respective doubling-times of 6 and 11 h.  Cells were then lysed with 
addition of lysis buffer (1M sodium acetate, pH 5.5, 1% Triton X-100) and 20 mg/mL 
phosphatase substrate (Sigma). After incubation for 3-6 h, absorbance was read at 304 nm. Dose-
response curves and EC50s were obtained (Microsoft Excel, DeltaGraph Pro v3.5, and GraphPad 
Prism v6). Drug combinations were studied by cytotoxicity assays with one drug at fixed 
concentrations while the other was varied, and vice versa. EC50s were then obtained for plotting 
isobolograms, and for calculating combination index values (CalcuSyn V1, Biosoft).  
 
Animal Studies. Protocols were approved by the Johns Hopkins IACUC.  Drug solutions were 
prepared immediately before use in 5% glucose vehicle.  Six week-old female CD1 mice were 
infected with T. brucei (MiTat 1.2 427, 5x104) intraperitoneally (ip) on day 0.  On day 1, after 
confirmation of parasitemia, animals were divided into groups (3 to 5 mice each), then treated 
once daily with (i) vehicle (200 L ip, 3 d), (ii) 3.5 mg/kg berenil (Sigma-Aldrich) (200 L ip, 3 d), 
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(iii) single dose of 17-DMAG ip (150 mg/kg (400 L) or 75 mg/kg (200 L)), (iv) multiple doses 
of 17-DMAG ip (30mg/kg (200 L ip, 5 d), 20 mg/kg (200 L ip, 5 d), 50 mg/kg (200 L ip, 
3d)), or (v) multiple doses of 50 mg/kg 17-DMAG orally (200 L by gavage, 5 d or 4 d).  Mice 
were weighed prior to infection and daily during first week; parasitemia was monitored in tail snip 






In vitro Anti-trypanosomal Activity of Parent Compounds. Initial studies were to determine 
whether structurally diverse Hsp90 inhibitors had cytotoxic activity against African trypanosomes 
in vitro.  Geldanamycin, radicicol, and CUDC-305 are from three different chemical scaffolds but 
all bind to the N-terminal ATP-binding pocket of Hsp90 and inhibit ATPase activity (24,40-42).  
Novobiocin binds the C-terminal domain (43).  Geldanamycin and radicicol had potent 
nanomolar EC50s against T. brucei (Table 1), in agreement with reported 50% growth inhibition of 
T. brucei at 40 nM geldanamycin (15).  CUDC-305 and novobiocin had micromolar activity.   
 
Table 1. Activity of Hsp90 inhibitors against trypanosomes in vitro  














































Novobiocin  180,000 ±  20,000 
a
Values are mean ± SD of at least 3 independent experiments.  r
2
 value for dose-response curves all exceeded 
0.99  
Published in part in (30). 
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Structure Activity Relationships on the Ansamycin Scaffold. Based on the impressive 
potency of geldanamycin, twelve related ansamycins were analyzed for structure-activity 
relationships (Tables 2 and 3). For some measure of therapeutic index, compounds were also 
evaluated against the mammalian cell line L1210 (mouse leukemia cells). Disruption of the 
geldanamycin quinone (compound 255108, Table 2) reduced activity severely against 
trypanosomes and moderately against L1210. Sterically demanding hydrazone moieties at R4 
(210753, 255112, 265482) substantially decreased activity against both cell types.  Modifications at 
C17 were well tolerated.  Replacement of the methoxy at R1 with hydroxyl (255104) decreased 
potency some ten-fold against both cell types, but incorporation of chloroethylamino (320877) 
had little to no effect on potency.  Importantly however, other amino moieties at R1 enhanced 
selective toxicity against trypanosomes: a primary amine (255109) or allyl amino (330507) resulted 
in a 30- to 50-fold increase in selectivity, and dimethylaminoethylamino (707545) increased 
selectivity 300-fold.  An even more substantial change, a large, rigid bromo-benzoxazine bridging 
R1 and R2 positions (255105), maintained good activity against both cell types, suggesting this 
position is not constrained in the drug and target interaction. Modifications in more remote 
ansamycin ring substituents and reduction of the quinone (330500, Table 3) impaired potency 
and selectivity, while opening the macrocycle (265481) resulted in complete loss of activity.   
 
The general trends of these structure activity relationships correlate with crystal structure 
data of ansamycins complexed with mammalian Hsp90, where C17 modifications are solvent-
exposed and outside the Bergerat-fold ATP-binding pocket (44).  However, the series also reveals 
differences in susceptibility of mammalian and trypanosome cells.  Many factors may account for 
this including phylogenetic differences in the target enzymes.  This possibility is supported by the 
several log difference in ATPase activity of kinetoplastid HSP83 compared with mammalian 
Hsp90 (45).  Compounds with most favorable selectivity were 17-AG (255109), 17-AAG 
(330507) and 17-DMAG (707545); the latter was also most potent against trypanosomes.  As 17-
AAG is the most widely studied, its anti-trypanosomal effect was characterized more fully.   
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Table 2. Structure activity relationships of ansamycins 
Ansamycin Scaffold                             
NSC Number 
                          Modification               EC50 (nM)
a 














H 38000 7100 0.2
c
 




255112 OCH3 CO CO N NCH O 13000 9600 0.7 
265482 OCH3 CO CO N NCH
 
3400 5800 2 
255104 OH CO CO H 130 180 1 
320877 NH
Cl
 CO CO H 17 21 1 
255109 NH2 CO CO H 6.0 180 30
c 
330507        
17-AAG NH  
CO CO H 38 1800 50
c 













CO H 27 23 0.9 
a
Values are mean of at least 3 independent determinations.  Coefficients of variation for EC50 values were all 
≤33%.  r
2
 value for dose-response curves all exceeded 0.98; within an assay the coefficients of variation for 
quadruplicate determinations were ≤10% and averaged 2.1%.  
b
Ratio L1210 EC50 to T. brucei EC50; large numbers 
are favorable.  
c
P< 0.05 in two-tailed t-test comparison of T. brucei and L1210 values. 
Published in (30).   
15 
 
Table 3. Structure activity relationships on the ansamycin scaffold 
NSC Number       Structure 
EC50 (nM)
a 




























>80,000 >80,000 N/A 
a
Values are mean of at least 3 independent determinations. Coefficients of variation for EC50 values were all 
≤35%. r
2
 value for dose-response curves all exceeded 0.98; within an assay the coefficient of variation for 
quadruplicate determinations were ≤10% and averaged 2.6%.  
b
Ratio L1210 EC50 to T. brucei EC50; large numbers 
are favorable.  
c
P < 0.05 in two-tailed t-test.  N/A, Not Applicable. 
Published in (30). 
 
 
Additional Effects of 17-AAG. Heat shock chaperones were initially recognized as proteins 
whose levels increased after heat stress.  Hsp90, among other chaperones, helps maintain protein 
quality control.  We hypothesized that if 17-AAG inhibits HSP83, then 17-AAG might sensitize 
trypanosomes to heat shock.  In control cells a 1 h heat pulse caused a 10 h arrest in 
trypanosome cell growth (Fig. 6).  In a dose-dependent fashion, 17-AAG sensitized 
trypanosomes to heat shock.  Cells shocked in 30 nM 17-AAG (ordinarily an EC30) continuously 





Figure 6.  T. brucei treated with 17-AAG are more sensitive to heat shock.   
Starting at -1.5 h, cells at 37 °C were treated with 17-AAG or solvent as indicated.  Control cells 
continued at 37 °C for the remainder of the experiment.  At -1 h, tubes containing cells to be heat 
shocked (HS) were transferred to a 41°C water bath, then returned to 37 °C at 0 h for the remainder 
of the experiment.  Motile cells were counted by hemocytometer to determine parasite density.  
Values are mean ± SD of three determinations. Published in (30).   
 
Somewhat surprisingly, trypanosomes differ from mammalian cells, and Hsp90 inhibitors did 
not synergize with etoposide, bortezomib, melarsoprol, pentamidine or novobiocin (Fig. 7). 17-
AAG and etoposide, melarsoprol, or novobiocin was moderately antagonistic, whereas 17-AAG 
and bortezomib or pentamidine was severely antagonistic (Fig. 7).  
 
Activity of 17-DMAG in T. brucei-infected Mice. The promising in vitro cytotoxicity of 
Hsp90 inhibitors supported evaluation in a mouse model of T. brucei infection. Three 
experiments were carried out with 17-DMAG. 17-DMAG was chosen for superior water 




   Drug                 Combination Index Values 
         ED50                    ED75             ED90 
Etoposide 1.42 1.49 1.61 
Bortezomib 2.01 1.90 2.0 
Melarsoprol 1.83 1.59 1.35 
Pentamidine 1.94 1.66 1.57 
Novobiocin 1.13 1.06 1.00 
 
Figure 7. 17-AAG is not synergistic in combination with five other compounds 
(A) EC50 isobolograms of 17-AAG in combination with each of five other drugs show no synergism.  
The concentrations of 17-AAG and partner drug required to produce a 50% growth inhibition in 
combination were plotted as a fraction of the concentrations of each as a single agent required to 
produce a 50% growth inhibition.  All combinations show an antagonistic effect, falling to the right 
and above of the dotted additive EC50 line.  (B) Combination Index (CI) values for 17-AAG 
combinations.  Values are means of ≥ 2 experiments.  1 defines additivity, <1 is synergistic, >1 is 
antagonistic.  CI values were calculated for a mutually nonexclusive mechanism of action; except for 
novobiocin which was calculated for a mutually exclusive mechanism of action (novobiocin also 






vehicle controls and caused death within four days (Fig. 8). Veterinary anti-trypanosomal Berenil 
cured all mice. Three dosing strategies were used with 17-DMAG; a single high dose on day 1, 
multiple doses ip, or multiple doses orally. All provided initial clearance of parasitemia and 
prolonged survival relative to controls.  A single high parenteral dose of 150 mg/kg led to dose-
limiting toxicity, and day 10 recurrence of parasitemia in the surviving mouse (Fig. 8A).  When 
this same total dose was divided over five days as 30 mg/kg a day, parasitemia dropped below 
detection by day 3 and all mice were cured, i.e., without detectable parasitemia for thirty days 
(Fig. 8A).  Reducing the ip dose to 20 mg/kg for five days cured three out of five mice (Fig. 8B), 
reducing the number of doses to three days of 50 mg/kg cured two out of four mice (Fig. 8C), 
and a single ip dose of 75 mg/kg did not cure but prolonged survival an average of 7 days (Fig. 
8C). Of considerable importance, oral 17-DMAG (50 mg/kg daily for 5 days) caused prompt 
reduction in parasitemia and cured three out of four mice in experiment A, and three out of five 
mice in experiment B (Fig. 8A,B). The mice which died had been clear of parasitemia for four or 
more days, so likely died from gavage-induced trauma and/or drug toxicity. Oral 17-DMAG 
dosed at 50 mg/kg for 4 days also cured four out of five mice, with one dying from toxicity (Fig. 
8B). The remaining mice in these groups appeared healthy and remained parasite-free for 30 d.  
Weight change as an index of health was consistent with these outcomes.  In experiment A, on 
day 0 the average weight was 21.6 g.  Between days 0 and 7 average weight changes were: +2.2 g 
(Berenil), -0.75 g (17-DMAG, 150 mg/kg ipx1), +3.5 g (17-DMAG, 30 mg/kg ipx5), and +3.2 g 
(17-DMAG, 50 mg/kg oralx5).  
 
 
Figure 8. 17-DMAG has anti-trypanosomal activity in vivo.   
Mice were infected with T. brucei on day 0.  Starting on day 1 they were treated once daily with 
vehicle or drug as indicated then monitored for up to 30 d for survival and parasitemia (average value 
for group) by visual analysis and hemocytometer counts of trypanosomes in tail snip blood samples. 
Negative control in blue, positive control in yellow, single ip doses in green, multiple ip doses in red, 









African sleeping sickness, caused by the protozoan parasite Trypanosoma brucei, is universally 
fatal if untreated and current drugs are limited by severe toxicities and difficult administration.  
New antitrypanosomals are greatly needed.  Hsp90 is a conserved and ubiquitously expressed 
molecular chaperone essential for stress responses and cellular signaling. Hsp90 inhibitors were 
investigated for their anti-trypanosomal activity.  Several inhibitors with different chemical 
scaffolds (namely certain ansamycins and resorcinols) had potent activity in vitro against 
bloodstream form T. brucei; purine CUDC-305 and C-terminal inhibitor novobiocin had 
micromolar activity.  In structure–activity studies of geldanamycin analogs, 17-AAG and 17-
DMAG were most selective against T. brucei compared to mammalian cells.  Despite important 
differences, major structural requirements on the ansamycin scaffold are similar for anti-
trypanosomal and anti-tumor activities, likely due to the high degree of conservation between the 
HSP83 and mammalian Hsp90 ATP binding pockets (46).  
 
17-AAG treatment sensitized trypanosomes to heat shock. These two stressors potentiate 
each other, likely due to a lower capacity of the trypanosome Hsp90 system to help buffer heat 
damage. Interestingly in antitrypanosomal cytotoxicity assays 17-AAG did not synergize with five 
other compounds. Etoposide and bortezomib were each tested in combination with 17-AAG 
due to reported synergy against cancer cells (47,48). The lack of synergy in trypanosomes may 
result from many factors, including alternative regulation of damage responses and death 
pathways, or divergence in drug targets. Bortezomib and 17-AAG were decidedly antagonistic; 
perhaps the downstream damage from proteasome inhibition relies on HSP83 function or vice 
versa. Novobiocin was used to assess the combination of an N-terminal and C-terminal Hsp90 
inhibitor; however the combination was not beneficial for efficacy. Melarsoprol and pentamidine 
were tested as partner drugs to assess the interaction of 17-AAG with these commonly used 
clinical antitrypanosomals. The substantial antagonism observed between 17-AAG and 




Both oral and parenteral 17-DMAG cured mice of a normally lethal infection of T. brucei. 
Single doses provided substantial survival benefits over controls, with parasitemia reappearing on 
day 7 with 75 mg/kg ip treatment and on day 10 with 150 mg/kg ip; however, were unable to 
cure mice. Single dose 150 mg/kg was toxic to the mice, with two out of three mice dying on 
days 4 and 9 after having cleared the initial parasitemia. Multiple doses of 17-DMAG were 
curative, with 50 mg/kg ip for three days curing two out of four mice, and 20 mg/kg ip for five 
days curing three out of five mice. 30 mg/kg ip for five days achieved 100% cures. In oral 
experiments, 50 mg/kg was given for four or five days and led to cure of parasitemia. 
Unfortunately, dosing 50 mg/kg a day by gavage for four or five days led to death of one out of 
five, and three out of nine mice respectively, a week after parasitemia had cleared and several 
days after dosing had finished. As 17-DMAG is only 50% bioavailable in mice (49), it seems 
unlikely that this toxicity was caused by systemic 17-DMAG, as 30 mg/kg ip for five days was 
well tolerated. Dosing by oral gavage is traumatic for the mice and 17-DMAG is known to cause 
gastrointestinal toxicity (50), so the gavage dosing may have potentiated the 17-DMAG 
gastrointestinal toxicity in some way leading to death in susceptible animals. The rest of the mice 
appeared healthy. 17-DMAG can cure aggressive mouse trypanosomiasis, both ip and orally, 
crucial proof of therapeutic index for 17-DMAG against trypanosomes.  
 
Hsp90 inhibitors can be potent and selective anti-trypanosomal agents, as clearly 
demonstrated by in vitro cytotoxicity assay activity and more importantly by cure of acute mouse 
trypanosomiasis. Given the 61% protein sequence identity between Hsp90 and HSP83, it is 
interesting to speculate on the basis for this therapeutic index.  Precedent for selective toxicity to 
Hsp90 inhibitors exists in the up to 200-fold greater susceptibility of tumor cells compared to 
non-transformed cells (36,51).  Cancer cells are thought to be unusually dependent on Hsp90 to 
chaperone up-regulated oncogene clients and mutant proteins and to counter the toxic metabolic 
environment commonly present in tumors (33-36).  The unique cellular pathways in 
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trypanosomes suggest downstream processes, not present in host cells, which may be unusually 
dependent on HSP83.  These include the heat shock-sensitive requisite trans-splicing of a 5'-
leader sequence onto all mRNAs (16) (disruption of which would globally cripple protein 
synthesis), or the production of essential variable surface glycoprotein for the cell surface coat 
(which requires chaperone activity) (52,53).  Trypanosomes also have less stringent checkpoints 
lowering the threshold for cell cycle disruption (19).   
 
The promising in vitro and in vivo activity of Hsp90 inhibitors against trypanosomes 
supports further investigation of their potential for clinical development for human African 





CHAPTER II. Chemical or genetic interference with trypanosome Hsp90s 
causes cell cycle dysregulation 
Published in part in: 
Meyer, K. J., and Shapiro, T. A. (2013) Potent antitrypanosomal activities of heat shock protein 
90 inhibitors in vitro and in vivo. J Infect Dis 208, 489-499 (30) 
 
INTRODUCTION 
The protozoan kinetoplastid parasite Trypanosoma brucei causes human African 
trypanosomiasis (sleeping sickness) (1). Kinetoplastids, including human pathogens T. cruzi and 
Leishmania sp., are early diverging eukaryotes named for the kinetoplast, the characteristic dense 
granule of DNA at the base of the flagellum that comprises the mitochondrial genome. The 
kinetoplast is visible by light microscopy and is a unique structure composed of a network of 
thousands of interlocking plasmids of DNA (Fig. 9A). Several dozen 20-30 kb ‘maxicircles’ 
contain protein coding genes, but the majority of kinetoplast DNA (kDNA) is 1 kb ‘minicircles’ 
which encode guide RNAs to help edit maxicircle transcripts (54). The complex kinetoplast 
network has to be replicated faithfully once per cell cycle and is thus a carefully timed and 
regulated process (Fig. 9B), which differs dramatically from the mitochondrial DNA replication 
of mammalian host cells. Replication and separation of the kinetoplast precedes that of the 
trypanosome nucleus (Fig. 9B), and is linked to the separation of the basal bodies that nucleate 
the flagella. Once the kinetoplast, nucleus, and each substructure in the trypanosome has been 
replicated and precisely positioned, cytokinesis occurs via cleavage furrow ingression (55). The 
complex temporal requirements of these processes, coupled with a lack of tight checkpoints 
characteristic in higher eukaryotes, make trypanosomes particularly vulnerable to cell cycle 
disaster (19,56,57).  
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Figure 9. Kinetoplast replication in T. brucei  
(A) Electron micrograph of an isolated kDNA network from T. equiperdum. Black arrow highlights a 
minicircle, clear arrow highlights a maxicircle. Bar is 1 M. Reprinted from (58) with permission from 
Elsevier (License number 3833661438027). (B) In trypanosomes both the nuclear and the 
mitochondrial genomes can be visualized by light microscopy, and their replication is temporally 
linked but not strictly synchronous.  Cells progress from having one nucleus and kinetoplast (1N1K), to 
one nucleus and two kinetoplasts (1N2K), and finally to two nuclei and kinetoplasts (2N2K) before the 
cells divide by cleavage furrow ingression to yield two daughter cells (adapted from (56)). G1, Gap 1; 
SK/N, Synthesis kinetoplast/nuclear DNA; G2, Gap 2; D, Kinetoplast division; M, Nuclear mitosis; P, 





In mammalian cells several important cyclins, cyclin dependent kinases, and other cell cycle 
regulators, such as Polo-like and Aurora kinase, are clients of the molecular chaperone, Hsp90. 
Hsp90 inhibition leads to various cell cycle malfunctions in different cell types. The kinetoplastid 
homologue of Hsp90 is HSP83, with T. brucei carrying ten tandem copies of HSP83 in its genome 
(14).  Initial studies have suggested that the Hsp90 inhibitor geldanamycin does cause cell cycle 
arrest in kinetoplastids L. donovani and T. cruzi, however, this has not been characterized in detail 
(59-61). Little is known about the role of HSP83 in T. brucei cellular metabolism and its clients 
and co-chaperones remain to be identified.  As in mammalian cells, HSP83 does interact with 
deacetylase Sir2 in Leishmania and with protein phosphatase 5 in T. brucei (15,62).  There are 
several forms of Hsp90 in mammalian cells. Hsp90 and Hsp90 differ in transcriptional 
regulation and are found throughout the cell, and there are two organelle Hsp90s, TRAP-1 in the 
mitochondria and GRP94 in the endoplasmic reticulum. TRAP-1 and GRP94 have only 34% and 
49% identity to Hsp90/ and may have different evolutionary origins (11). They both contain a 
conserved Bergerat fold in the N-terminus for ATP binding and hydrolysis, but their C-termini 
differ substantially, likely reflecting different interactions with other proteins and specific 
functions (63). TRAP-1 in mammalian cells has been implicated in apoptosis pathways, 
protection from oxidative stress, mitochondrial dynamics, and mitochondrial metabolism (64).  
 
Cell cycle defects due to the Hsp90 inhibitor 17-AAG and arising from selective genetic 




MATERIALS AND METHODS 
Cell Culture and Reagents. All studies used bloodstream form T. b. brucei maintained in HMI9 
(phenol red-free, 10% FBS, 10% Serum Plus) at 5% CO2, 37°C. For work with 17-AAG, MiTat 
1.2 strain 4.7 was used. RNAi was carried out in the Single-Marker Bloodstream (SMB) line 
(obtained from ATCC) in HMI9 (made with tetracycline (Tet) tested FBS) containing G418 (2.5 
g/mL) to maintain dual expression of the Tet repressor and T7 RNA polymerase (65). 17-AAG 
was obtained from the Open Chemical Repository of the Developmental Therapeutics Program 
(National Cancer Institute) and stored aliquoted in DMSO at -20°C.  
 
Flow Cytometry. For each time-point, 3x106 cells from treated cultures (seeded at 2x105 
cells/mL) were pelleted (1000xg, 10 min), washed twice (glucose and sucrose supplemented PBS: 
vPBS (66)), fixed by dropwise addition of ice-cold 70% EtOH (PBS), and stored (4°C).  Cells 
were pelleted (3000xg, 10 min), washed (PBS), resuspended in 500 L 10 g/mL RNaseA (PBS), 
and incubated (37°C, 45 min).  After addition of propidium iodide (Sigma-Aldrich) (final, 
20 g/mL), 10,000 cells were analyzed on a FACSCalibur (BD Biosciences), gated on FL2-A vs 
FL2-W to exclude doublets, and the G1 peak of controls centered at 200 units FL2-A (CellQuest 
Pro v5.2, BD Biosciences).   
 
DAPI Staining and Fluorescence Microscopy. For whole cell DAPI staining of 50 nM 17-
AAG treated cells, at each time-point 2x106 cells from treated cultures (seeded at 2x105 cells/mL) 
were pelleted (1000xg, 10 min), washed (vPBS), fixed with 3% paraformaldehyde (PBS) (10 min 
on ice), diluted 5-fold (vPBS), pelleted (3000xg, 10 min), washed (vPBS), applied to polylysine-
coated slides (1 h), permeabilised with 0.1% Triton X-100 (Sigma-Aldrich) (PBS) (10 min), 
washed thrice (PBS), and mounted using Fluoroshield with DAPI (Sigma-Aldrich) (66). For 100 
nM 17-AAG treated cells and RNAi experiments, a simpler method was used. 1x106 cells were 
centrifuged at 1000xg for 10 min and supernatant aspirated to 50 L. Pellet was resuspended and 
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25 L spread on a glass slide and left to dry. Slide was immersed in ice cold methanol for at least 
1 h, then air dried. DAPI-containing mounting medium (Fluoroshield) was used to mount a 
coverslip. Cells were imaged on a Zeiss Axioskop with Retiga Exi charge-coupled-device camera 
(QImaging Corp) using iVision v4.0.13 (Biovision Technologies).  
 
TdT Labelling. 5x106 -1x107 trypanosomes (seeded at 2x105 cells/mL) were spun (1000xg for 
10 min) and washed in 1 mL vPBS. Supernatant was removed to 100 L, pellet resuspended, and 
100 L lysis buffer (10 mM Tris.HCl, 75 mM EDTA, pH 8.0, 1% SDS) containing 2 mg/mL 
proteinase K added and incubated (55°C for 2 h). After storage at 4°C, RNaseA (final 
concentration 0.1 mg/mL) was added and incubated at 37°C for 30min-1h. 300 L of 20% 
sucrose in TE was layered underneath the lysate, and spun (13000 rpm for 30 min). Supernatant 
was aspirated to 100 L and washed with 700 L of TE. Supernatant was removed to 50 L, and 
networks resuspended. Networks (20 L) were then settled on to 8-well Teflon coated slides 
(pre-treated with 0.01% polylysine) for 1 h. Networks were equilibrated with terminal 
deoxynucleotidyl transferase (TdT) reaction buffer (plus 2.25 mM CoCl2) for 20 min (Roche), 
then incubated with reaction buffer including 2.25 mM CoCl2, 10 M dATP, 5 mM Fluorescein-
12-dUTP (Thermo Scientific), and 10 U TdT (Roche) for 1 h. Reaction was quenched (2xSSC, 
three times for 5 min each), networks were washed twice with PBS, stained with 5 g/mL DAPI 
(in H2O) for 15 min, washed thrice with PBS, and then sealed using Vectashield mounting 
medium (Vector). Networks were imaged on a Zeiss Axioskop with Retiga Exi charge-coupled-
device camera (QImaging Corp) using iVision v4.0.13 (Biovision Technologies). 
 
Southern Blots. To isolate DNA for Southern analysis, 2x106 cells (seeded at 2x105 cells/mL) 
were pelleted (1000xg, 10 min) and washed with vPBS. Pellet was resuspended in lysis buffer (10 
mM Tris.HCl, 75 mM EDTA, pH 8.0, 1% SDS) containing 2 mg/mL proteinase K (Invitrogen) 
and incubated at 55°C for 2 h. After storage at 4°C, RNase A was added (final concentration 0.1 
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mg/mL) and incubated at 37°C for 1 h. Samples were mixed with DNA loading dye, loaded on 
20 cm agarose gels (1.5% or 0.6%) and run at 70 V for 17 h in TBE (90 mM Tris/Borate, 2.5 
mM EDTA), 1 g/mL EtBr. Gels were processed in 0.25 N HCl (15 min); rinsed in H2O (10 
min); neutralized in 0.6 M NaCl, 0.2 M NaOH (45 min); and finally incubated with 25 mM 
sodium phosphate (pH 6.5, 30 min x2) and transferred overnight in 10xSSC onto nylon 
Amersham Hybond™-N+ membrane (GE Healthcare). Membranes were cross-linked twice with 
1200 J UV. To probe the membranes, T. equiperdum full length minicircle DNA (1 kb excised 
from pJN6 with SmaI and XbaI) (67), or a 770 bp maxicircle sequence (amplified from whole cell 
DNA using 5′-CTAACATACCCACATAAGACAG-3′ and 5′-ACACGACTCAATCAAAGCC-
3′) was radiolabeled with [32P]-ATP using random primers (Invitrogen) and Klenow polymerase 
(37°C, 1 h), purified through Sephadex-G50, and hybridized with membranes in Church-Gilbert 
solution (0.5 M NaHPO4, pH 7.2, 1 mM EDTA, 7% SDS, 1% BSA (68)) overnight at 45°C. 
Membranes were washed thrice (1xSSC, 0.1% SDS) at 45°C and exposed to PhosphorImager 
(Fuji) plates that were then scanned (Fuji Bas 2500 PhosphorImager, ImageGauge v3.45 Fuji). 
 
RNAi of Trypanosome Hsp90s. The sequences of human TRAP1 mRNA variants 
(NM_016292.2 and NM_001272049.1) were compared to the T. brucei Lister Strain 427 genome 
sequence on TriTrypDb using the blastn program with an expectation value of 10, resulting in 
the identification of (Tb427tmp.02.0250/Tb11.02.0250), a putative heat shock protein, with an E 
value of 6e-12 (69). RNAiT software (TrypanoFan)(70) was used to choose a 487 bp sequence 
for HSP83 (Tb10.26.1080/Tb927.10.10980) and a 592 bp sequence for putative TbTRAP 
(Tb427tmp.02.0250) that had no greater overlap than 20/21 bp with any other sequence in the 
trypanosome genome (Appendix I). These RNAi sequences were amplified from T. brucei whole 
cell DNA (HSP83 and TbTRAP genes lack introns) incorporating 5’ XbaI/XhoI and 3’ 
NdeI/AscI sites, then sequentially inserted in to the plew100v5X:pex11 vector (71) as inverted 
repeats using XhoI/AscI digestion and then XbaI/NdeI digestion. Primers used were: HSP83 
forward XbaI 5’-CCC CTC TAG ATA TTG TGA AGA AGG CCC TGG-3’, XhoI 5’-CTC 
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TCT CGA GTA TTG TGA AGA AGG CCC TGG-3’; HSP83 reverse NdeI 5’-CCC CCA TAT 
GCT CTT TCA TTG CCT TGC ACA-3’, AscI 5’-CTT TGG CGC GCC CTC TTT CAT TGC 
CTT GCA CA-3’; TbTRAP forward XbaI 5’-CCC CTC TAG AGA GCT CTC CTT TTG CAC 
ACC-3’ , XhoI 5’-CTT CCT CGA GAG CTC TCC TTT TGC ACA CC-3’; TbTRAP reverse 
NdeI 5’-CCC CCA TAT GTG TGA ACC TGG TCG GTA CAA-3’, AscI 5’-GTA TGG CGC 
GCC TGT GAA CCT GGT CGG TAC AA-3’. Correct insertion was confirmed by sequencing 
across insertions sites in both directions. The vectors were amplified in E. coli DH5, purified, 
linearized with NotI, and transfected in to SMB T. brucei constitutively expressing the Tet 
repressor and T7 RNA polymerase (65). Transfection was performed using Human T-cell 
Nucleofector™ (Lonza) and an AMAXA electroporator on program X-001. 1x107 cells were 
transfected with 10 g DNA and immediately diluted into 30 mL of HMI9. A further 1:10 
dilution was made. Both dilutions were then plated into 24 well plates. After 6 h, 2.5 g/mL 
phleomycin was added to each well to select for transfectants. Three independent rounds of 
transfection were performed generating 11 clones for HSP83 RNAi and 12 clones for TbTRAP 
RNAi. Tet (100 ng/mL) was added to induce RNAi.  
 
Tagging TbTRAP with cmyc. Endogenous TbTRAP was tagged with a terminal 3xcmyc-tag 
using homologous recombination. The terminal 400 bp sequence of TbTRAP minus the STOP 
codon was ligated in frame into a modified pMOTag33M vector (72) (modified to contain a 
blasticidin resistance gene) using Kpn1 and XhoI. The first 400 bp of the 3’UTR sequence from 
TbTRAP was ligated into the vector using BamHI and SacI. The sequences were amplified from 
genomic DNA using the high fidelity PfU Turbo DNA Polymerase (Agilent), isolated on a 1% 
agarose gel (TBE) and purified using a Qiagen Gel extraction kit. The vector was amplified in 
DH5 E.coli. Kpn1 and SacI were used to digest out the fragment containing the TbTRAP 
terminal sequence, cmyc tag, blasticidin resistance gene, and TbTRAP 3’UTR, and this fragment 
was electroporated into 2x107 cells of a TbTRAP RNAi clone (in SMB cells) using LONZA 
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Nucleofector™ as described above. Transfectants were selected using blasticidin pressure (5 
g/mL) and 6 out of 43 were chosen for clonal dilution and analysis.  
 
Northern Blots. 1x107 cells (seeded at 2x105 cells/mL) were centrifuged (1000xg, 10 min) and 
supernatant removed to 10 L. RNA was purified using a Qiagen RNeasy Mini kit (350 L 
Buffer RLT, vortex, 350 L 70% EtOH, RNeasy column, wash RWI and RPE x2, eluted with 30 
L water). RNA concentration was measured using a NanoDrop™ (Thermo Scientific) and 700 
ng mixed with formaldehyde loading dye (Invitrogen), heated at 65°C for 15 min, cooled on ice, 
mixed with EtBr (final 12.5 g/mL) and loaded on to a formaldehyde (6.6%) agarose (1%) gel 
cast and run in MOPS (20 mM MOPS, 8 mM NaOAc, 1 mM EDTA, pH 7.0). The gel was run at 
5V/cm for 3 h. Gel was then processed in 1M NH4OAc for 45 min, and the RNA transferred 
with 1M NH4OAc overnight onto nylon Amersham Hybond™-N+ membrane, then crosslinked 
with 2x 1200 J UV. Membranes were wet in 2xSSC, pre-hybridized in Church-Gilbert solution 
for ≥1 h, and probed with random primer radiolabeled [32P]-dATP template (labeled as described 
for Southern blots) overnight at 56°C. Templates were gene sequences outside of the RNAi 
region that had no more than 40 bp overlap with other T. brucei genes. HSP83 template 413 bp, 
primers 5’CCAGAGTCTGACGAACCAGTC3’, 5’ CCAGGTATTCCTGCTGGTCT3’; 
TbTRAP template 525 bp, primers 5’CTAAAGGGCAATGCAGGGGA3’, 
5’CCGGCTGTACACCTTGACAT3’. Membranes were washed thrice (1xSSC, 0.1% SDS) at 
56°C and exposed to PhosphorImager (Fuji) plates that were then scanned (Fuji Bas 2500 
PhosphorImager, ImageGauge v3.45 Fuji). 
 
Western Blots. 5x106 cells (seeded at 2x105 cells/mL) were centrifuged (1000xg, 10 min), 
washed twice in vPBS, and supernatant aspirated to 20 LSDS loading dye was added (6 L, 6 
X) and sample boiled for 5-10 min in a boiling water bath then stored at 4°C. Samples were 
warmed to room temperature, loaded on an acrylamide gel (5% stacking, 8% running) and run at 
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200 V for 45 min in SDS-PAGE buffer. Proteins were transferred to Amersham Hybond™-ECL 
(GE Healthcare) membrane at 100 V for 1 h at room temperature. Blots were blocked in 5% 
milk, washed twice with TTBS (20 mM Tris.HCl, 1.5 M NaCl, pH 7.6, 0.1% Tween-20), 
incubated with primary antibody overnight at 4°C (1:5000 Hsp90 (sc-7947, H-114, lot e2611, 
Santa Cruz Biotechnology), 1:500 cmyc (C3956, Sigma), in 5% BSA in TTBS), washed three time 
with TTBS, incubated with secondary antibody at room temperature for 1 h (1:30000 goat-
antirabbit-HRP in 5% BSA in TTBS, sc-2054, Santa Cruz Biotechnology), and washed thrice 
with TTBS. Blots were developed with “ECL Plus” western blotting detection system (RPN2132, 
Amersham Biosciences) and imaged on an Image Station 4000R Pro (Kodak) with Carestream 




17-AAG Affects Growth Rate, Mitosis and Cytokinesis. Previous reports indicate that for 
insect form T. cruzi or L. donovani, 24 h geldanamycin treatment arrests the cell cycle at either G1 
or G2 (59-61).  Within 5 h, 50 or 100 nM 17-AAG (EC80 or EC99, respectively) arrested growth of 
bloodstream T. brucei and cell numbers declined thereafter (Fig. 10).  Cell cycle progression was 
inhibited, and this was examined by flow cytometry and microscopy of DAPI-stained cells, 
across time and concentration.   
 
Figure 10. 17-AAG arrests trypanosome growth and kills trypanosomes 
Trypanosomes were treated with indicated concentrations of 17-AAG or vehicle control (DMSO) and 
cell concentration counted over 48 h. n ≥ 2. Error bars SD for n ≥ 3. 
 
Figure 11. The cell cycle of T. brucei is disrupted by 17-AAG 
Trypanosomes were treated with solvent, 50 nM 17-AAG, or 100 nM 17-AAG for the indicated times 
then examined by flow cytometry for propidium iodide staining. This method focuses on the nuclear 
genome as kDNA comprises only 5% of total cell DNA (73). (A) Histograms of 10000 cells. (B)(C)(D) 
Quantification (n ≥ 5, means±SD) for DMSO, 50 nM 17-AAG and 100 nM 17-AAG respectively. G1, Gap 
1; S, Synthesis; G2/M, Gap 2/Mitosis; 2C, non-replicating diploid cells with two copies of nuclear 
genomic DNA; 4C, cells late in replication with four copies of genomic DNA; 6C or 8C, abnormal cells 






Based on nuclear DNA content as measured by flow cytometry, control cultures in mid-log 
growth were 38% G1 (2C DNA content for the diploid trypanosome), 21% S, and 35% G2/M 
(4C DNA content).  This distribution was maintained until the culture reached stationary phase 
at 24 h (Fig. 11).  50 nM 17-AAG caused a transient increase in the G1 peak at 5 h, which 
decreased progressively thereafter.  At 10 h the G2/M (or 4C) peak was increased, indicating a 
problem with mitosis and/or cytokinesis.  At 24 h the 4C peak remained significant, but 
substantial 6C and 8C peaks were also present.  These abnormal forms are possible in 
bloodstream trypanosomes due to inadequate or missing checkpoints to stop re-replication of 
DNA when cytokinesis is delayed or inhibited (19).  With 100 nM 17-AAG the 5 h increase in G1 
and 10 h increase in G2/M (or 4C) were also seen, but at 24 h the dominant population was 4C, 
along with an 8C but no 6C peak.  With both concentrations the percentage of cells in S phase 
declined (Fig. 11).   
 
To obtain further insight into this cell cycle disruption, trypanosomes were examined by 
fluorescence microscopy.  Unlike flow cytometry, which reflects nuclear DNA content, visual 
analysis of DAPI-stained cells assays both nuclear and kinetoplast DNA, and phase contrast 
provides concomitant analysis of cytokinesis.  Control cells can be divided into three populations.  
First, 1N1K cells, with a single nucleus and kinetoplast, are 68% of the total; second, in 1N2K cells 
mitochondrial DNA has divided but nuclear mitosis has not occurred (21%); and finally, in 2N2K 
cells the kinetoplast and nucleus have both divided (8%) (Fig. 12Ai-iii, B).  These proportions are 
in good agreement with flow cytometry: G1 plus S (38+21%) are a subset of 1N1K (68%); and 
1N2K plus 2N2K (21+8%) are a subset of G2/M (35%) (Fig. 11B).  Likewise consistent with 
flow cytometry, treatment with 50 nM 17-AAG reduced 1N cells, and increased 2N cells and 
forms containing greater than 2N (Fig. 12B).  Simultaneous accounting for both nuclei and 
kinetoplasts revealed the vivid loss of coordinate replication of these genomes.  Flawed nuclear 
mitosis was evidenced by cells with abnormally high numbers of kinetoplasts but only one or two 
giant nuclei (Fig. 12Ci, ii).  Conversely, defective kinetoplast segregation, with unchecked nuclear 
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mitosis, produced cells with multiple nuclei and a single large kinetoplast, demonstrated 
numerically by the increase in 2N1K cells (Fig. 12B; Ciii, iv).  Grouping cells by ratio of nuclei to 
kinetoplasts established kinetoplast segregation as more defective than nuclear mitosis: 29% had 
more nuclei than kinetoplasts (Fig. 12D).  Of cells that retained a ‘normal’ census of nuclei and 
kinetoplasts, many still had evident dysregulation, including 2N2K cells whose kinetoplasts had 
begun to re-replicate prior to cytokinesis (Fig. 12Cv).  Phase contrast confirmed the cytokinesis 
inhibition suggested by 6C and 8C flow cytometry peaks.  At 24 h cells with multiple partially 
ingressed cleavage furrows indicated repeated failed attempts at cell division (Fig. 12Ci,iii) and 
some cells were arrested at abscission (Fig. 12Cvi).   
 
Figure 12. 50 nM 17-AAG causes multiple cell cycle abnormalities 
Analyses of trypanosome nuclear and kinetoplast content by DAPI staining and fluorescence 
microscopy.   (A) Examples, as indicated, of normal 1N1K, 1N2K and 2N2K cells in control cultures; 
bar, 1µm.  (B) Trypanosomes were treated with 50 nM 17-AAG or solvent for the indicated times, 
then scored for nuclear and kinetoplast content based on DAPI staining.  Values are the means ± SD of 
counts made in a blinded fashion by three observers.  Insert shows nuclear content of ‘Other’ cells 
across time.  X, ≥5, Z, not-identifiable (C) Examples of aberrant cells after 24 h 50 nM 17-AAG. White 
arrowhead, re-replicating kinetoplast (D) Panel B data analyzed to determine percentage of cells with 
number of nuclei equal to, less than, or greater than kinetoplasts. Published in (30).  
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Interestingly, abnormalities from 100 nM 17-AAG were substantially less varied.  There was 
a large increase in 2N populations (including aberrant 2N1K) (Fig. 13A), but few trypanosomes 
had more than two nuclei or kinetoplasts. Once again the increased 2N population correlated 
with the flow cytometry result of increased 4C DNA content, although the substantial 8C peak in 
flow cytometry suggests that some of these 2N cells have undergone a second round of nuclear 
DNA synthesis without mitosis. There was also a large increase in trypanosomes displaying a 
partially ingressed cleavage furrow, primarily seen with 2N cells (Fig. 13B,C), and in keeping with 
the number of nuclei this was primarily one cleavage furrow and not multiple in contrast to  
 
Figure 13. 100 nM 17-AAG causes cytokinesis defect 
Analyses of trypanosome nuclear and kinetoplast content by DAPI staining and fluorescence 
microscopy. (A) Trypanosomes were treated with 100 nM 17-AAG for the indicated times, then scored 
for nuclear and kinetoplast content based on DAPI staining. (B) Examples of aberrant cells after 12 h 
treatment with 100 nM 17-AAG. Bar, 1M. (C) Percentage of 2N cells with a visible partially ingressed 
cleavage furrow after treatment with 100 nM 17-AAG. Mean±SD, n ≥ 3. n > 100 cells were counted for 
each condition. 
 
Figure 14. Kinetoplast separation is impaired with 17-AAG treatment. 
(A) Trypanosomes were treated with 100 nM 17-AAG for the indicated times, then scored for nuclear 
and kinetoplast content based on DAPI staining, and kinetoplasts were further scored as either single 
(Ks), elongated (Ke), proximal (Koo), or clearly separated (Ko o). (B), (C), (D) Percentage of total, 1 N, 
or 2 N cells, respectively, with different kinetoplast morphologies. Values are the means ± SD of three 








50 nM (Fig. 12Ciii). The strong 2N1K population prompted a closer look at kinetoplast 
morphology. Cells were scored according to presence of single, elongated, proximal, or fully 
separated kinetoplasts (Fig. 14). The percentage of cells containing a single kinetoplast or clearly 
separated kinetoplasts decreased, and elongated kinetoplasts increased, suggesting 17-AAG 
treatment slows kinetoplast separation (Fig. 14B). This is clearly seen when looking at just 2N 
cells (Fig. 14D), with the percentage containing fully separated kinetoplasts decreasing from 90% 
at 0 h to just 25% by 12 h. The separation defect worsens over time with increasing percentages 
of 2N cells containing proximal and elongated kinetoplasts.  The presence of a cleavage furrow 
and an abnormal kinetoplast were not clearly correlated suggesting these processes are likely due 
to separate pathway malfunctions. 
 
To test whether structurally different Hsp90 inhibitors caused cell cycle disruption, cells were 
treated with 350 nM radicicol (EC99) (Fig. 15). The same broad patterns were seen by microscopy 
and flow cytometry (Fig. 15A,B), indicating the effects are likely attributable to HSP83 inhibition. 
 
Figure 15. Radicicol causes cell cycle dysfunction 
Trypanosomes were treated with 350 nM radicicol for 24 h. (A) Examples of aberrant cells using DAPI 
staining, fluorescent and light microscopy. (B) Quantifications of flow cytometry histograms of 
radicicol treated cells stained with propidium iodide to measure nuclear DNA content. G1, Gap 1; S, 
Synthesis; G2/M, Gap 2/Mitosis; 6C or 8C, abnormal cells with six or eight copies of the nuclear 




The multiple abnormalities caused by Hsp90 inhibitors suggest that HSP83 deficiency affects 
several cell cycle proteins.  At sub-maximal inhibition the lack of effective checkpoints results in 
abnormal nuclear and kinetoplast content and abortive cytokinesis.  With more stringent 
inhibition of HSP83 the regulated ability of cells to initiate and complete kDNA segregation and 
cytokinesis is more severely impaired which limits the variety of abnormalities.  Overall, and 
different from previous reports with the insect forms of other kinetoplastids (59-61), these 
results indicate time- and concentration-dependent disruption of both G1 and G2/M phases.    
 
17-AAG Slows Kinetoplast Division. Mitochondrial kDNA replication is a fascinating process 
unique to trypanosomatids, the regulation of which is very complex (54). As a solution to the 
topological problem of duplicating a catenated network, minicircles are decatenated from the 
network for replication (Fig. 16). The daughter minicircles are reattached at opposite poles of the 
network without closing all replication gaps, perhaps a book-keeping tool to ensure complete 
replication of all minicircles (54). This leads to a growing oval shaped network. At the final stages 
of replication the network appears dumbbell shaped, the gaps in the minicircles are filled, and the 
network divides into two new round networks (Fig. 16).  The free minicircles have different 
topological forms depending on their progress through replication.  Released as covalently closed 
plasmids, a theta structure is formed while the polymerase is synthesizing new strands.  The 
daughter minicircles are either ‘gapped’, or ‘nicked’, depending on whether the new strand of 
DNA was the continuously synthesized leading strand or the lagging strand of Okazaki 
fragments (Fig. 16).  Each of these forms runs at a different speed on an EtBr containing agarose 
gel.  17-AAG treatment (100 nM) led to a transient decrease in actively replicating theta 
structures and nicked daughters at 4 h, then a small increase in protein-bound linears over the 
next 20 h (Fig. 17A). 17-AAG also caused an increase in free maxicircles over 24 h (Fig. 17B). 




Figure 16. Kinetoplast DNA network replication schematic 
A single network (circle) replicates minicircles gradually via decatenation of covalently closed plasmids 
then polymerase replication via a theta structure to produce a ‘gapped’ daughter (leading strand) or 
‘nicked’ daughter (lagging strand). These daughters are reattached at opposite poles of the network 
without ligation of all gaps (grey). This process leads to a growing network that is at first oval and 
finally dumbbell shaped. When all minicircles have been replicated, the gaps are filled and ligated and 
the network divides to two new single round networks. Adapted from Theresa Shapiro. 
 
Kinetoplast networks were isolated from 17-AAG treated cells, spread on slides, and the 
gaps in DNA filled in with fluorescent nucleotides to reveal the progress of kDNA replication 
(Fig. 18). With just 2 h of 100 nM 17-AAG treatment (2 h) there was a significant decrease in 
partially replicated networks (labeled poles), and an increase in fully labeled dumbbell-shaped 
networks. This suggests lagging initiation of replication, but also problems with closing minicircle 
gaps and separating daughter networks. After 4 h, labeled dumbbells declined whilst abnormal 
populations of first fully labeled ovals, followed by unlabeled ovals, became significant (together 
over 40% of networks by 24 h).  This positioning and segregation defect suggests decatenation 
problems, perhaps due to the topoisomerase defects evidenced by the protein-bound linear 
minicircles (Fig. 17). These results explain the increased elongated kinetoplasts and the 2N1K 
population in whole-cell DAPI staining (Fig. 14).  
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Figure 17. Free minicircles and maxicircles in cells treated with 17-AAG 
DNA from cells treated with 100 nM 17-AAG was separated on agarose gels, transferred to nylon 
membranes, and probed with a kDNA minicircle (A) or maxicircle (B) sequence. Lanes were loaded by 
cell equivalents. O – Oligos, T – Theta structures, G – Gapped minicircles, N – Nicked minicircles, L – 
Linears, CC – Covalently closed minicircles. 
 
Figure 18. TdT labelling of kinetoplast networks from 17-AAG treated trypanosomes 
Networks were isolated from 100 nM 17-AAG treated cells, spread on slides, stained with DAPI (red) 




RNAi of HSP83. To further explore the role of trypanosome HSP83 in cell cycle regulation, 
RNAi constructs were generated to knock-down HSP83. The ten tandem copies of HSP83 are 
99.7% identical and thus a single RNAi sequence was sufficient to knock-down all gene products 
(Appendix I). The sequence selected for RNAi was inserted into the plew100v5X:pex11 vector 
(71), which integrates into an rRNA spacer region of the trypanosome genome and expresses the 
RNAi sequence as a stem-loop construct under a Tet controlled rRNA promoter. SMB 
trypanosomes were the recipient cells, containing both T7 RNA polymerase and the Tet 
repressor under a single neomycin resistance gene (G418 selection) (65). Three independent 
rounds of transfection were carried out, giving rise to 11 clones resistant to phleomycin 
(plew100v5X:pex11 carries a Sh ble gene). These clones were tested for growth phenotypes on 
addition of Tet to initiate RNAi. 9 out of 11 displayed a similar rapid and severe growth defect. 
Interestingly, although the growth defect was rapid cell kill was slow and took several days 
(representative clone Fig. 19A). Northern blotting was used to confirm that HSP83 mRNA 
decreased on addition of Tet, although across 48 h mRNA was never completely ablated  
 
Figure 19. HSP83 RNAi causes rapid and severe growth defect. 
(A) Cumulative cell growth of a representative clone carrying plew100v5X:pex11 configured for HSP83 
RNAi, plus or minus Tet addition. Numbers adjusted for dilutions, which occurred each time 
concentrations exceeded 1x10
6
/mL in order to maintain log growth. (B) Northern probing HSP83 
mRNA on the same representative clone treated with Tet. Tubulin probed as a loading control. (C) 
Western blot using a human Hsp90 antibody on the same representative clone treated with Tet. 





(Fig. 19B).  Protein lysates were probed with several human Hsp90 antibodies, and SC-7947 
(Santa Cruz) detected a band between 80-90 kDa that decreased significantly with Tet treatment, 
but like the mRNA was not completely ablated (Fig. 19C).  
 
Cell cycle progression after RNAi induction was investigated through DAPI staining and 
fluorescent microscopy. HSP83 RNAi caused a large increase in 2N2K cells, a substantial 
cytokinesis defect (Fig. 20). This defect was at or prior to cleavage furrow initiation, as the 
number of 2N cells containing a visible cleavage furrow did not increase significantly (Fig. 20C). 
At 48 h a small 2N1K population accumulated. KDNA replication was investigated with a free 
minicircle profile, which showed an increase in abnormal linears at 48 h (Fig. 21). A census of 
network shapes and labeling patterns with TdT found decreased partially replicated forms and 
substantial populations of labeled and unlabeled ovals (Fig. 22), confirming kinetoplast 
segregation lesions and explaining the 2N1K population. 
 
 
Figure 20. HSP83 RNAi inhibits cytokinesis  
HSP83 RNAi cells were treated with Tet and examined by DAPI staining and fluorescent microscopy 
for cell cycle progression. (A) Nuclear and kinetoplast contents of cell population. Cells counted for 
each time point ≥ 100. (B) Representative image of 2N2K cells. Bar, 1 M. (C) Percent of 2N cells with 






Figure 21. HSP83 RNAi leads to an increase in linear minicircles at late timepoints 
DNA from HSP83 RNAi cells was separated on a 1.5% agarose gel and probed with a minicircle 
sequence. Lanes were loaded by cell equivalents. O – Oligos, T – Theta structures, G – Gapped 
minicircles, N – Nicked minicircles, L – Linears, CC – Covalently closed minicircles. 
 
Figure 22. Abnormal TdT labeled and unlabeled ovals increase in HSP83 RNAi cells 
Networks were isolated from HSP83 RNAi Tet induced cells, spread on slides, stained with DAPI (red) 
and labelled with fluorescent dUTP (green) using TdT. Networks ≥1500 counted for each treatment. 
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RNAi of TbTRAP. A BLAST search was performed against the trypanosome genome with the 
human mitochondrial Hsp90, TRAP-1, sequence (69). Tb427tmp.02.0250 was identified as a 
homologue with an Expect value of 2e-151 in predicted amino acid sequence with 62% positive 
and 43% identical matches. The Expect value for the mRNA sequence was 6e-12 with 68% and 
75% identity in a 177 bp and 91 bp segment of the genetic sequence. Tb427tmp.02.0250 is 
annotated as a putative heat shock protein, and contains a mitochondrial targeting sequence. In 
the literature, Tb427tmp.02.0250 was identified as part of the trypanosome mitochondrial 
proteome (74). Hereafter Tb427tmp.02.0250 is termed TbTRAP. As with HSP83 RNAi, a 
portion of TbTRAP was cloned into the plew100v5pex11 vector, and then transfected into SMB 
trypanosomes. Three independent rounds of transfection were carried out, giving rise to 12 
clones. All 12 displayed a similar post 48 h growth defect on addition of Tet (Fig. 23A). 
Northern blotting was used to confirm that TbTRAP mRNA decreased (Fig. 23B). A human 
TRAP antibody was tested but did not detect any correctly sized bands in western blots. In one 
clone an endogenous copy of TbTRAP was tagged at the C-terminus using homologous  
 
Figure 23. TbTRAP RNAi causes growth defect after 48 h  
(A) Cumulative cell growth of eleven clones carrying plew100v5X:pex11 configured for TbTRAP RNAi, 
plus or minus Tet. Numbers adjusted for dilutions when cells concentrations exceeded 1x10
6
/mL in 
order to maintain log growth. Mean±SD, n=11 (B) Northern probing TbTRAP mRNA on a 
representative clone treated with Tet. HSP83 probed as a loading control. (C) Western blot against 
cmyc of a TbTRAP RNAi cell line with an endogenous copy of TbTRAP modified to carry a C-terminal 





recombination to insert a 3xcmyc tag and a blasticidin resistance gene in between the 3’ end of 
the TbTRAP coding sequence and the 3’UTR. Six blasticidin resistant clones were subjected to 
Tet treatment and to western probing with a cmyc antibody. Four clones expressed a band 
between 80-90 kDa that decreased after 72 h of Tet treatment (Fig. 23C). These clones retained 
the same growth defect on Tet addition, but two clones lost their sensitivity to Tet and in these 
clones the 80-90 kDa band did not decrease.  
 
In both the parent clones and in a cmyc tagged clone (that retained the same Tet induced 
growth defect) cell cycle progression was examined by microscopy. Interestingly, concurrent with 
the growth defect an abnormal 1N0K population, lacking a visible kinetoplast, appeared and 
increased with prolonged RNAi, and a small 2N1K population built up (Fig. 24). 1N0K cells are 
possible either when there is a kinetoplast replication defect without a cytokinesis defect, so that 
one daughter cell receives a kinetoplast and one does not, or when the cleavage furrow is 
positioned so that one daughter receives two kinetoplasts and the other none. As there was no 
increase in 1N2K cells, and there was evidence of 2N1K cells at abscission (Fig. 24B), the former 
scenario of a strong kinetoplast replication defect with no concomitant cytokinesis defect is  
 
Figure 24. TbTRAP RNAi causes abnormal 1N0K cells and 2N1K cells 
TbTRAP RNAi cells were treated with Tet and examined by DAPI staining and fluorescent microscopy. 
(A) Nuclear and kinetoplast contents of cell population. At 0 and 72 h error bars are SD for n ≥ 3. Cells 




likely. This is in contrast to the cell cycle defects observed with 17-AAG treatment and HSP83 
RNAi, but unsurprising if TbTRAP is indeed a mitochondrial Hsp90 as there would be no need 
to suppose it chaperoned cytokinesis regulators.   
 
The free minicircle population was investigated and simultaneous with the growth defect a 
vivid alteration occurred. Replicating minicircle intermediates (theta and nicked smears) vanished, 
and multiple forms of abnormal oligomers appeared (Fig. 25). These changes point to an 
inhibition of kDNA synthesis and topoisomerase difficulties with catenation and decatenation of 
minicircles. Interestingly imaging of TdT labeled networks did not reveal vivid changes, although 
there was a small but significant increase in abnormal labeled and unlabeled oval networks, as had 
been seen with 17-AAG treatment and HSP83 RNAi (Fig. 26). This, together with the DAPI 
whole cell staining (Fig. 24), suggests a strong halt on kinetoplast replication. TbTRAP is 
essential for kDNA integrity. 
 
Figure 25. TbTRAP RNAi causes abnormal free minicircle populations  
DNA from TbTRAP RNAi cells was separated on a 1.5% agarose gel and probed with a minicircle 
sequence. Lanes were loaded by cell equivalents. O – Oligos, T – Theta structures, G – Gapped 




Figure 26. Abnormal TdT unlabeled ovals increase in TbTRAP RNAi cells 
Networks were isolated from TbTRAP RNAi Tet induced cells, spread on slides, stained with DAPI (red) 






17-AAG causes rapid growth-defects in trypanosomes. In higher eukaryotes, the toxicity of 
Hsp90 inhibitors is attributed to subsequent functional loss of client proteins, which include key 
cell cycle regulators.  There was vivid evidence of cell cycle dysregulation in trypanosomes treated 
with Hsp90 inhibitors.  Many gene products essential for orderly progression through the 
trypanosome cell cycle have been identified via RNAi silencing, including kinases (e.g., cyclin-
related, Aurora, Polo-like (PLK), nuclear DBF-2 related (NDR) (75-77)) and kinase regulators 
(e.g., cyclins, kinase activator MOB1, kinase receptor TRACK (78-80)), several of whose 
mammalian homologs are recognized Hsp90 clients (81-84).  Individual knockdown of these 
proteins in kinetoplastids generates a cell cycle defect, such as abnormal numbers of kinetoplasts 
or nuclei, arrested or misplaced cleavage furrows.  Unlike these discrete phenotypes, however, 
with Hsp90 inhibitors multiple abnormalities were seen in the same cell and pleomorphic 
abnormalities in the population (Fig. 12C).  These complex and profound disruptions of nuclear 
and kinetoplast segregation and cytokinesis support the notion that HSP83, like Hsp90 in higher 
eukaryotes, is an important node in the midst of numerous regulatory pathways. Cytokinesis and 
kinetoplast segregation defects dominate at high concentrations of 17-AAG suggesting key 
regulators of these processes are clients particularly sensitive to loss of Hsp90 function.  
 
Initiation and completion of cleavage furrow ingression was impaired after 17-AAG 
treatment with many cells containing a visible partially ingressed furrow. Cell cycle proteins 
found particularly associated with this process are PLK, NDR kinases and their activator MOB1, 
and TRACK, along with cytoskeletal associated proteins such as katanins and kinesins (85-88). 
RNAi silencing of these genes leads to incomplete cleavage of the cell or failure to initiate 
cleavage furrow ingression (77,79,80,87,88). PLK is a client of mammalian Hsp90, and thus an 
attractive candidate for being the sensitive HSP83 client in T. brucei responsible for the cleavage 
furrow defects observed. Kinetoplast replication was also disrupted with 17-AAG treatment, 
particularly the architectural positioning of newly replicated minicircles and the dividing of the 
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network. Topoisomerases play an important role in this process, as do many other proteins, some 
of which have not yet been identified (54).  
 
RNAi of HSP83 and of Tb427tmp.02.0250, putative TbTRAP, led to inhibition of growth, 
proving both of these genes are essential for T. brucei. This confirms the severe growth defect 
observed in bloodstream forms after HSP83 knockdown in a genome wide RNAi screen of T. 
brucei (89). Tb427tmp.02.0250 was not identified as essential in bloodstream forms in that 
genome wide screen, but our observation of a delayed growth defect explains its absence. In the 
same screen, it was found to be essential in procyclics, the insect form of T. brucei. Procyclics, 
unlike glycolytic bloodstream forms, rely on electron transport for energy production. Human 
TRAP-1 plays a role in the mitochondrial electron transport chain (64), and TbTRAP may also 
chaperone trypanosome components of this essential process in procyclics. In bloodstream 
forms, simultaneous with growth defects, we observed a halting of kinetoplast replication with 
RNAi of TbTRAP. Cells lacked kinetoplasts, or had two nuclei but only one kinetoplast (Fig. 24). 
There was a marked decrease in replicating theta and nicked minicircles and also an increase in 
catenated oligomers (Fig. 25). This suggests problems with the topoisomerases that ensure the 
correct catenation and decatenation of minicircles. The delay in appearance of this phenotype 
suggests a need to reach a threshold of dysfunction in certain kinetoplast replication regulators, 
the timing of which is likely determined by the size and rates of turnover of the protein pools of 
TbTRAP and of its clients. The growth defect due to RNAi of HSP83 was immediate, even 
without complete loss of HSP83 protein by western blot. This likely reflects the importance of 
having abundant HSP83, so that even with a small amount of protein loss sensitive clients are 
unable to function correctly. Although the growth defect was rapid, cells took 48 h to begin to 
die, consistent with the delayed death seen with 17-AAG treatment (Fig. 10 and 19). The major 
cell cycle defect seen was cytokinesis inhibition, along with a more delayed kinetoplast replication 
defect. Perhaps HSP83 in the cytosol chaperones a nuclear encoded but mitochondrion targeted 
protein essential for kDNA network architecture. The phenotype observed with HSP83 RNAi 
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was very similar to that observed with 17-AAG treatment, suggesting HSP83 is indeed the target 
of 17-AAG in trypanosomes. The RNAi phenotypes and 17-AAG treatment outcomes were not 
identical, which is unsurprising considering the difference between the gradual loss of protein 
that occurs with RNAi versus rapid chemical inhibition of ATPase activity with drug treatment. 
Cytokinesis and kinetoplast replication are particularly sensitive to chemical and genetic inhibition 
of Hsp90s in T. brucei.   
    
The tightly coordinated duplication in trypanosomes of the mitochondrial genome within the cell 
cycle differs dramatically from mitochondrial DNA replication in mammalian cells. KDNA 
sensitivity to loss of TbTRAP suggests that this mitochondrial Hsp90 chaperones certain key 
regulators of kDNA replication. HSP83 chaperones multiple cell cycle regulators, with 
cytokinesis and kinetoplast replication particularly sensitive to HSP83 loss. These results validate 
HSP83 as a target for anti-trypanosomal agents.   
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CHAPTER III. Hsp90 inhibitors display class-wide concentration-driven 
efficacy against Trypanosoma brucei 
 
INTRODUCTION 
Drug action, and ultimately clinical response, is determined by pharmacokinetic-
pharmacodynamic (PK-PD) relationships, the connection between drug exposure and effect. 
Understanding these relationships allows rational and optimal use of medicines. This is 
imperative in an era where incisive drug development, and control of drug toxicity and resistance, 
are critical needs. Drugs have dynamic concentration-time curves in vivo, with the typical pattern 
in blood after an oral dose being a rapid rise to the maximum concentration, Cmax, followed by 
decay at a rate corresponding to the half-life (t1/2). The resulting area under the concentration-
time curve (AUC) comprises total exposure to drug (Fig. 5). Crucially, shape of the curve (and 
correspondingly, shape of its AUC) can be manipulated by dosing strategy, resulting in striking 
differences in the outcome of drug action (PK-PD reviewed in (28,29,90)).  
 
 Total drug exposure (AUC) is an integral of concentration and time, thus for the same total 
exposure peak concentration is inversely related to the time drug levels are sustained above a 
threshold (Fig. 27). One useful PK-PD relationship is the simplistic discrimination between 
concentration- or time-driven activity, reflecting better efficacy from a steep or flat 
concentration-time curve, respectively. For some agents there is apparently no shape preference, 
in which case total AUC is said to determine efficacy. Famously the antibacterial penicillins are 
time-driven and require sustained levels to exert maximal clinical effect (91). The tendency in 
drug development is to lengthen the half-life of candidates, assuming this will improve activity 
and require less frequent dosing; however, for a peak concentration-driven drug the resulting 
constant and extended exposure can be inappropriate for efficacy, toxicity, and the risk of 
resistance (90). For example, the antibacterial activity of aminoglycosides depends on peak 
concentration and is not enhanced by sustained drug levels, which worsen their nephrotoxicity 
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(92,93). Likewise the antileukemia bcr-abl kinase inhibitor dasatinib (t1/2 3 h) has maximal 
efficacy and minimal toxicity dosed once rather than twice daily, consistent with the in vitro 
finding that a 20 min exposure is sufficient to trigger apoptosis (94,95). Highly short-lived 
artemisinins, the last line of drug defense against malaria, are efficacious with once daily dosing 
(96). For these drugs, with varying targets and therapeutic indications, brief intermittent 
exposures are adequate, indeed optimal, for activity. Requiring long half-lives for drug candidates, 
while ideal for time-driven compounds, may needlessly cause useful leads to be abandoned. 
Likewise, frequent dosing to maintain sustained concentrations may be unnecessary and perhaps 
detrimental. As the kinetic governance cannot be predicted, experimental determination of PK-
PD relationships is needed for ideal drug management.  
 
 
Figure 27. Peak concentration is inversely related to time above a threshold for the same 
total AUC 
Theoretical PKs depicted for the same total AUC (shaded) with t1/2 1x (blue), t1/2 4x (purple) or from a 
constant infusion (red). 
 
In vitro PK-PD methodologies are a valuable translational support. From the very earliest 
stage of drug discovery, determination of PK-PD can direct choice of lead compound and 
optimization of PK properties. PK-PD can be used to predict dosing regimens with greatest 
likelihood of efficacy in vivo. Post-clinical introduction, in vitro PK-PD can provide 
complementary support to explore alternative dosing regimens and clinical questions difficult to 
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address in patients. Hollow fiber cartridge systems, culture vessels perfused by porous polymer 
fibers that allow diffusion of small molecules but restrict passage of cells, are well established for 
the study of antibacterial and antiviral PK-PD (97,98). Our group developed a novel apparatus 
for PK-PD of antimalarials (99). This work describes, to our knowledge the first, dynamic in 
vitro PK-PD studies with Trypanosoma brucei. A simple but powerful method is proposed, 
conducted with artificial PK conditions, to identify the principal kinetic driver of a compound's 
efficacy.  
 
Trypanosoma brucei is an ancient divergent eukaryotic parasite. It causes the neglected but 
deadly infection human African trypanosomiasis (sleeping sickness), passed to humans by the 
tsetse fly in rural regions of sub-Saharan Africa. As an extracellular parasite, it causes non-specific 
symptoms and is difficult to diagnose (2). Unfortunately the infection progresses to the CNS, 
where it becomes difficult to treat. Current therapies are less than desirable, requiring lengthy 
injection regimens and causing severe toxicities (1). The worst case of this is organic arsenical 
melarsoprol, the only option for treating the late-stage of the acute east-African subspecies. 
Melarsoprol causes a reactive encephalopathy leading to death in 2-10% of patients. The 
potential of repurposing Hsp90 inhibitors against T. brucei was investigated and it was found that 
17-(allylamino)-17-demethoxygeldanamcyin (17-AAG) and 17-(dimethylethylamino)-17-
demothxygeldanamycin (17-DMAG), derivatives of geldanamycin, were both potent and 
selective against the parasite (Chapter I)(30). Importantly, both were able to cure mouse acute 
early-stage infections, including when 17-DMAG was delivered orally (30). T. brucei contains an 
Hsp90 homologue, HSP83, encoded by ten tandem gene copies (14). HSP83 is 60% identical to 
human Hsp90, and contains the conserved Hsp90 N-terminal ATP binding site, the Bergerat fold 
(46). 
 
Geldanamycin and radicicol, a benzoquinone ansamycin and resorcinol respectively, are 
natural products and were two of the earliest identified Hsp90 inhibitors (20,41). They both bind 
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in the ATP pocket (Bergerat fold) of the N-terminal domain of Hsp90 (100). Their scaffolds 
have been derivatized extensively, comprising two of the three major chemical classes of Hsp90 
inhibitors (24). The first Hsp90 inhibitor to enter clinical trials for oncology was 17-AAG 
(tanespimycin) which displayed promising activity in multiple myeloma and Her2 positive breast 
cancer (24,101). Improving on 17-AAG in solubility and pharmacokinetics, 17-DMAG 
(alvespimycin) was the second ansamycin in the clinic (102). Building off of the resorcinol 
scaffold, half a dozen inhibitors have been tested in cancer patients, with the greatest experience 
obtained for NVP-AUY922 and STA-9090 (ganetispib)(24). A third major class of Hsp90 
inhibitors are fully synthetic compounds discovered through high-throughput screening, that are 
based off a purine scaffold and also bind in the ATP pocket (82). Several of these have oral 
formulations, and various selected pharmacokinetic properties, such as blood-brain barrier 
penetration for CUDC-305/Debio 0932 (42).  
 
Clinical work with Hsp90 inhibitors has thus far focused on cancer therapy, where most 
treatment regimens are prolonged cyclical schedules with doses at the limit of tolerability. These 
schedules and doses are unlikely to be optimal for protozoan parasites with very distinct lifecycles 
and cell biology. By understanding the pharmacokinetic-pharmacodynamic (PK-PD) 
relationships of anti-protozoan activity, we can further the potential of Hsp90 inhibitors for 
treating parasitic infections. PK-PD can be used to build a target product profile for lead 
compound optimization of Hsp90 inhibitors for parasites. PK-PD can also be used to guide 
dosing strategies for in vivo investigation of compounds. We desired to develop a method to 
expose trypanosome parasites to programmable dynamic concentration-time profiles of drugs in 
vitro. This requires dilution of drug from the system, but retention of parasites. In order to 
further investigate the potential of Hsp90 inhibitors against T. brucei, in this study a hollow-fiber 
cartridge methodology was developed for in vitro study of antitrypanosomal PK-PD and the 




MATERIALS AND METHODS 
Cell Culture and Reagents. T. b. brucei (MiTat 1.2 strain 427) were maintained in log growth at 
37°C, 5% CO2, in phenol red-free HMI9, 10% FBS, 10% Serum Plus (Sigma). Number of live 
(motile) parasites was determined by hemocytometer and light microscopy. Drug stocks were in 
DMSO, stored aliquoted at -20°C. 17-AAG and 17-DMAG were obtained from the Open 
Chemical Repository of the National Cancer Institute Developmental Therapeutics Program. 
NVP-AUY922 (LC Laboratories) and CUDC-305 (ChemieTek) were purchased. [3H]17-AAG 
(48.5 Ci/mmol, Moravek) was used as a tracer of 17-AAG drug levels.  
 
Cytotoxicity and Bioassays. 96-well plate cytotoxicity assays were performed as described 
previously (Chapter I)(39). Briefly, cells were seeded at 1 x 105 cells/mL in quadruplicate at 
various drug concentrations. At 24 h cells were lysed and phosphatase substrate added. After 3-6 
h incubation at 37°C, absorbance was read at 405 nm, and treated wells were compared to 
untreated control wells. For bioassay of drug concentrations, unknown samples were incubated 
with 1 x 105 cells/mL for 24 h, and compared to a standard curve of known drug concentrations. 
 
In vitro PK-PD system for T. brucei. Several systems were tested for in vitro PK-PD of 
antitrypanosomals (Fig. 28).  
A) Glass cartridge, blown by Adams and Chittendon, perfused by dialysis membrane 
1) 50kDa pore-size,  regenerated cellulose 28 mm membrane (Spectrum Labs), with 0 – 
200 gauge 27 perforations 
2) 1000 kDa pore-size, cellulose ester 15 mm membrane (Spectrum Labs) 
B) Glass cartridge, blown by Adams and Chittendon, capped with hydrophilic 
polytetrafluoroethylene 1 m pore-size membrane (JAWP02500, Millipore). 
C) One-compartment open dilution in 50 mL bottle 
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D) Hollow-fiber cartridges 
1) 0.1 m pore, mixed cellulose ester fibers (MidiKros, Spectrum Labs) 
2) 0.2 m pore, polypropylene fibers (Cellmax, Spectrum Labs) 
3) 30 kDa pore, polysulfone fibers (Cellmax, Spectrum Labs) 
4) 20 kDa pore, polysulfone fibers (C2011, FiberCell Systems) 
5) 0.1 m pore, polyvinylidene difluoride fibers (C2025, FiberCell Systems) 
 
 
Figure 28. In vitro PK-PD systems tested for antitrypanosomals 
(A) Glass cartridges were threaded through with dialysis membrane. Trypanosomes were cultured 
outside the membrane and PK profiles of drug pumped through the lumen. (B) Glass cartridges were 
sealed on each end with porous membrane. Trypanosomes were grown in the cartridge and PK 
profiles of drug were pumped through the membranes and cartridge. (C) Trypanosomes and t0 drug 
were placed in a bottle. Drug free medium was added to the bottle and fluid was removed by a tube 
placed at the meniscus. (D) Trypanosomes were grown in the extra-fiber space of hollow fiber 
cartridges, and drug solution either pumped through the fibers or pumped directly in to the extra-




To achieve dynamic PK profiles, a central reservoir contained a drug solution at desired t0 (initial) 
concentration. Using flexible platinum-cured silicone tubing (Masterflex, Cole-Parmer and 2-stop 
1.52 mm ID, IDEX Health & Science) and a precise peristaltic pump (IPC, Ismatec), drug was 
diluted out of the central reservoir by addition of drug free medium from an input reservoir while 
removing drug solution at the same rate. This changing drug solution was then pumped through 
the apparatus containing trypanosomes, except in the case of the open dilution (Fig. 28C) where 
trypanosomes were in the central reservoir. In the final system used, trypanosomes were cultured 
in the extra-fiber space of a C2025 (FiberCell Systems) cartridge and PK profiles were pumped 
directly into the extra-fiber space and then out via the lumen of the fibers. Cartridges were kept 
sterile, and rinsed thoroughly with 70% EtOH, water, then HMI9 between experiments. The 
standard PK-PD experiment involved three cartridges; one drug-free control cartridge, and two 
cartridges given the same total AUC and dose of drug but delivered in contrasting regimens to 
either favor time above a threshold or to favor Cmax. To achieve initial t0 drug concentrations, 
cartridges were pre-incubated with calculated concentrations of drug to satisfy non-specific 
binding to the fibers (Table 4). At t0, extra-fiber medium was replaced with trypanosomes at 
1x105 cells/mL and t0 drug levels, and the cartridge connected to a central and waste reservoir. 
Pumps were set to 0.45 mL/min (1.52 mm id two-stop tubing, Cole Parmer) and medium 
pumped continuously from an input reservoir to the central reservoir, and from the central 
reservoir into the extra-fiber space of the cartridge, across the fibers and out through the lumen 
of the fibers to waste. The control cartridge was exposed to drug-free medium.  To achieve the 
constant infusion (time-intensive) regimen, input and central reservoirs and cartridge contained 
the same concentration of drug. To achieve the Cmax regimen, the central reservoir contained 
drug at t0 levels, but the input reservoir contained drug-free medium, leading to a steady dilution 
of drug over time. To adjust half-life, volume of the central reservoir was adjusted. Half-lives 
were initially determined without cells in the extra-fiber space of the cartridge, sampling from the 
distal port and determining drug concentration using cognate radiolabeled tracer or bioassay. 
Half-lives were confirmed to be within 10% of desired for every drug. For PK-PD experiments, 
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the end point was removal of trypanosomes from each cartridge and determination of number of 
live parasites using hemocytometer and light microscope.   
 
Assessment of Non-specific Binding. Isolated cartridges were incubated with known high 
concentrations of drug. The extra-fiber space was sampled over time and drug concentration 
determined. At equilibrium, the percentage of drug loss was calculated and this value used to 
calculate the concentration required to pre-incubate cartridges to achieve t0 values for 
experiments (Table 4). In the range of concentrations studied, non-specific binding was 
concentration independent.   
 
Table 4. Hsp90 inhibitor non-specific binding and conditions to attain desired kinetics 
Drug Drug loss in 
cartridge (%)
a 
      Cartridge pre-incubation
b 




17-AAG 95 20 3 21 
17-DMAG 94 15 16 21 
NVP-AUY922 90 10 1 25 
CUDC-305 90 10 3 20 
a
Drug bound at equilibrium after incubation in an isolated cartridge with high drug concentration 
b
Conditions used for pre-incubation to compensate for nonspecific binding of drug to cartridge. Based on the 
percentage of drug lost, the indicated multiple (x) of the t0 drug concentration was incubated in the cartridge for 
indicated duration before start of experiment 
c
Volume in central reservoir for Cmax regimens to ensure t1/2 of 1 h in extra-fiber space of cartridge 
 
Statistical Analysis. Where indicated, an unpaired, two-tailed, equal variance Student’s t-test 
assessed significance. Modified Thompson’s Tau test was used on the 24 h trypanosome 
population in the control cartridge (% of parallel flask for uncontaminated experiments, n = 162) 




Establishment of an in-vitro PK-PD System for Antitrypanosomals. Multiple in vitro PK-
PD systems were tested for robust growth and recovery of trypanosomes, and reproducible 
desired pharmacokinetics (Fig. 28). Due to trypanosome motility, glass cartridges perfused by 
perforated dialysis membranes did not retain trypanosomes, and without perforation drug 
diffusion could not achieve desired pharmacokinetics (Fig 28A). Capping a glass cylinder with 
hydrophilic membrane and rapidly pumping PK profiles of drug through the system produced 
desired PK; however, membranes were toxic to trypanosomes (Fig. 28B). A one-compartment 
system with constant dilution was impractical due to near complete loss of trypanosomes over 24 
h (Fig. 28C). Five commercially available hollow-fiber cartridges were tested (Fig. 28D). The 
Cellmax systems with polypropylene or polysulfone fibers were toxic to trypanosome growth, 
even after extensive washing with HMI9. Trypanosomes grew in the cellulose Midikros and 
polysulfone C2011 cartridges; however, due to the density of fibers in the cartridge, recovery of 
trypanosomes was highly variable. Under final flow conditions in the polyvinylidene difluoride 
C2025 cartridge (FiberCell Systems), trypanosome growth initially equaled then surpassed that in 
parallel T25 vented flasks (Fig. 29). Extended viability may be due to constant provision of fresh 
nutrients and removal of byproducts.  
 
Figure 29. Trypanosomes grow well in C2025 cartridge with cross-fiber flow. 
Trypanosome growth in cartridges with flowing drug-free medium into extra-fiber space and across 




Figure 30. Standard circular loop flow path limits attainable PK parameters. 
(A) Schematic of standard circular loop design. Snapshot during a dynamic drug  dilution for a Cmax 
regimen, produced when a high starting concentration of drug (blue) in the central reservoir is diluted 
with medium (yellow to form green) from an input reservoir. This is circulated through the lumen of 
the fibers and back to the central reservoir. Medium is removed from the central reservoir to waste at 
the same rate as diluent enters from the input bottle. Arrowhead, site of directional pump. (B) Actual 
PK obtained for Hsp90 inhibitor 17-DMAG (red) in extra-fiber space of C2025 cartridge when pumps 
where set to achieve t1/2 1 h (Dotted curve). 
 
Early efforts to obtain desired PK profiles with conventional flow pathways in the C2025 
cartridge failed (Fig. 30), likely because of extensive nonspecific and reversible drug binding to 
fibers (Table 4). Pre-coating of fibers with polyethylene glycol, gamma globulins, or bovine 
serum albumin had no effect on PK. Likewise, pre-treatment with trypsin to destroy bound 
proteins did not improve PK. To circumvent the reversible binding, a single pass cross-fiber flow 
path was used, pumping medium directly into the extra-fiber space then into the lumen of the 
fibers and out to waste (Fig. 31). Pre-incubation with calculated concentrations of drug prior to 
PK-PD (Table 4) led to accurate t0 drug levels. Half-life was adjusted by varying the volume of 
the central reservoir and confirmed to be within 10% of desired in the extra-fiber space for all 
drugs tested. Flow rates were kept constant across experiments to control for effects on 
trypanosome growth. During PK-PD experiments, mean growth in the extra-fiber space at 24 h 
was 77 ± 13 percent (n = 127) that of flasks. In some 170 experiments (500 cartridges) over 24 
months, 45 cartridge results were discarded due to contamination, and 8 experiments were 
discarded due to poor control cartridge growth. Contamination by autoclave- and bleach-resistant 
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spores was traced to lab wipes and was significantly reduced after paper products were eliminated 
from cartridge set-up areas. 
 
Figure 31. PK-PD system for in vitro study of antitrypanosomals.  
Schematic of hollow fiber cartridge system. A snapshot during a dynamic Cmax regimen, produced 
when a high starting concentration of drug (blue) in the central reservoir is diluted over time with 
medium from an input reservoir (yellow, to form green). The ever-changing dilution is pumped into 
the extra-fiber space of a cartridge and out via the lumen of the fibers to waste. Parasites are 
maintained in the extra-fiber space. Arrowhead, directional pump.  
 
17-AAG is Concentration-driven Against T. brucei. To diagnose the intrinsic 
antitrypanosomal PK driver, two contrasting PK shapes are artificially generated of the same 
total drug exposure (AUC), a steady constant infusion (time-intensive) or a transient high peak 
(Cmax-intensive), and compared the efficacy against trypanosomes (Fig. 32)(103). The regimen 
that gives greater efficacy is designated the PK driver and has important implications for drug 
optimization and in vivo use. The constant concentration infusion maximizes the time drug is 
present above a threshold. To begin, experiments were 24 h, which allows four doubling times of 
untreated controls in log growth (T. brucei cell cycle is 6 h in our hands) and comparison to our 
standard 24 h cytotoxicity assays. To contrast the time-intensive regimen, a Cmax-intensive 
regimen of the same AUC0-24 was initially generated with t1/2 1 h (Fig. 32B). This ensures the drug 
concentration has dropped 98% over the length of one cell cycle, and generates a peak 16.8-fold 




Figure 32. 17-AAG is concentration-driven against trypanosomes. 
(A) Structure of the benzoquinone ansamycin 17-AAG. (B) The same total AUC (shaded) is dosed over 
24 h against trypanosomes as either a constant concentration infusion (red) or as a high peak that is 
rapidly cleared with t1/2 1 h (blue). Pharmacokinetics were confirmed by radioactive tracer in 
cartridges sampling (symbols) from the extra-fiber space. (C) An AUC0-24 720 nM•h of 17-AAG is 
significantly more efficacious dosed as a 500 nM peak with t1/2 1 h than as a constant infusion of 30 
nM. (D) Over 18 h, the same 17-AAG AUC0-18 of 540 nM•h is more effective dosed as a high peak of 
380 nM, t1/2 1 h, than as a 30 nM infusion. (E) Over 12 h, 17-AAG is more effective dosed as a 250 nM 
peak, t1/2 1 h, than as an infusion of 30 nM, resulting in the same AUC0-12 of 360 nM•h. Mean±SD, n≥3, 
* p<0.05, ** p<0.01. 
 
To begin 17-AAG was delivered at an AUC0-24 of 720 nM•h, for which the 30 nM infusion 
had an efficacy of 64%, in the linear dose-response range (Fig. 32C). When this same AUC0-24 
was dosed to favor Cmax, 504 nM with t1/2 1 h, 17-AAG was 95% effective (Fig. 32C).  When the 
shape of the PK curve favors peak concentration, 17-AAG has significantly greater efficacy. The 
length of the experiment was varied to examine the effect of end-point on the PK driver of 17-
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AAG. Trypanosomes were exposed to an infusion of 30 nM, and the equivalent AUC as a high 
Cmax, t1/2 1 h, for 18 h or 12 h (Fig. 32D,E). In all cases the Cmax regimen was more efficacious. 
17-AAG efficacy is concentration- rather than time-driven. 
 
17-AAG Exposure-response Curve Shifts Left When PK Shape is Cmax-intensive. Multiple 
AUC0-24s of 17-AAG were dosed in the two contrasting ways, time-intensive infusion or Cmax-
intensive (t1/2 1 h) transitory peak, to obtain full exposure-response curves for these different PK 
shapes (Fig. 33). The exposure-response curves were significantly separated. The greatest vertical 
efficacy separation was seen at an AUC0-24 of 300 nM•h, where infusion dosing was just 20% 
effective, but by shifting the same AUC0-24 to a transient high Cmax 90% efficacy was obtained. 
The linear portions of the curves were horizontally separated three-fold. The EA50 ‘potency’ of 
17-AAG with Cmax-intensive (t1/2 1 h) dosing was 190 nM•h versus 610 nM•h for time-intensive 
infusion. These exposure-response curves demonstrate the significantly greater benefit that is 
obtained when the shape of 17-AAG exposure is Cmax-intensive. For the greatest efficacy with 
the least total exposure, 17-AAG is most efficiently dosed by transient high peak concentrations.  
 
Figure 33. 17-AAG is more potent dosed as Cmax-intensive PK shape. 
Trypanosomes were exposed to 17-AAG in contrasting PK shapes, as either constant infusions (time-
intensive, red), or as rapidly cleared high peaks (Cmax-intensive, t1/2 1 h, blue), and efficacy determined 
at 24 h compared to untreated control.  
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17-AAG Exposure Shape is Optimal with the Highest Peak. To further examine PK shape 
preference, the relationship between peak, half-life, and efficacy was determined. The same total 
AUC0-24 of 480 nM•h was dosed with a t1/2 of 1 h, 2 h, 4 h, or as a constant infusion (Fig. 34A). 
As the half-life increased and the Cmax decreased, the efficacy decreased (Fig. 34B). Cmax is the 
strongest driver of 17-AAG efficacy, with the greatest effect obtained from an AUC0-24 by 
delivering it as the highest peak, and therefore most transient exposure.   
 
 
Figure 34. 17-AAG is most effective dosed with the highest peak and shortest half-life. 
Trypanosomes were exposed to the same total AUC of 17-AAG of 480 nM•h over 24 h with t1/2 1 h 
(blue), 2 h (lavender), 4 h (violet), or as a constant infusion (red). (A) Pharmacokinetics were 
confirmed by sampling (symbols) cartridges for all regimens. (B) 17-AAG at an AUC0-24 of 480 nM•h 
was most effective with the highest peak concentration and shortest half-life (340 nM, t1/2 1 h) and 
least effective as a constant infusion of 20 nM. Mean±range/SD, n≥2. 
 
Three Hsp90 Inhibitors from Different Chemical Classes are Concentration-driven. There 
are multiple different chemical classes of Hsp90 inhibitors in the clinic. The ansamycins (e.g. 17-
AAG) were the original class to enter clinical development; however, the most promising 
candidates are now from the resorcinol and purine scaffolds (Fig. 4). The intrinsic PK driver was 
tested for the ansamycin 17-DMAG, the resorcinol NVP-AUY922, and the purine-based CUDC-
305 (Fig. 35). Each of these Hsp90 inhibitors, with very different chemical structures, were more 
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efficacious dosed as a Cmax-intensive regimen (t1/2 1 h) than as a time-intensive constant infusion 
(Fig. 35). This suggests a class wide concentration-driven activity for Hsp90 inhibitors, regardless 
of chemical structure.  
 
 
Figure 35. Hsp90 inhibitors from three chemical scaffolds are concentration-driven. 
The same AUC0-24 was more effective dosed as a Cmax-intensive regimen (blue, t1/2 1 h) than as a time-
intensive constant infusion (red). (A) Benzoquinone ansamycin 17-DMAG, (B) resorcinol NVP-AUY922, 




In vitro PK-PD methodologies are valuable translational tools for studying drugs. However, 
in order to be able to study in vitro PK-PD a system is needed that provides robust maintenance 
of the organism of interest, recovery for PD purposes, and accurate and reproducible delivery of 
adjustable PK profiles. With trypanosomes we encountered difficulty with either retaining and 
supporting robust growth, or recovering accurate numbers of cells. The other foremost difficulty 
was obtaining the PK profiles we desired to study. Without large porous surface areas, diffusion 
did not produce rapid equilibration between extra-membrane/fiber and luminal spaces. 
Reversible drug binding to system components also greatly hindered attainment of correct peaks 
and then rapid dilution of drug. These problems were solved by pre-incubating cartridges to 
reach equilibrium at free desired t0 levels, and then active pumping of drug PK profiles into the 
space containing trypanosomes (the extra-fiber space) and then across the porous fiber 
membranes and out to waste. In this set-up, the fibers act as a filter retaining the trypanosomes 
but allowing drug and medium components to pass through. Although this system places 
trypanosomes under a constant flow pressure, at the flow rate used (0.45 mL/min) trypanosome 
growth was equivalent to that of control populations in flasks (Fig. 29), and constant fluid flow is 
the in vivo condition of trypanosomes in the bloodstream.  
  
17-AAG has potent activity against African trypanosomes. This activity is a function of the 
shape of the exposure, as separate dose-response curves are generated based on dosing that is 
either Cmax- or time-intensive (Fig. 33). The activity of 17-AAG is concentration-driven. When 
delivered as high peak concentrations (with t1/2 1 h) 17-AAG is even more ‘potent’ than constant 
concentration infusions, generating the same effect with a three-fold lower AUC or total 
exposure to drug. In other words, Cmax dosing is more efficient than infusion dosing, as a lower 
total exposure to 17-AAG is needed for maximal efficacy against trypanosomes. If the AUC of 
17-AAG is on the linear portion of the dose-response curves, changing the shape of the AUC in 
these contrasting ways can mean the difference between almost no activity as a constant infusion 
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but almost complete activity as a high Cmax t1/2 1 h. The versatility of in vitro hollow fiber PK-PD 
systems allowed us to generate these contrasting shapes and to explore artificial PK conditions. 
For a single AUC, the half-life was varied from 1, to 2, to 4 h, and compared to constant infusion 
dosing. The efficacy decreased with increasing half-life and therefore decreasing Cmax (Fig. 34). 
Peak concentration is the strongest driver of 17-AAG efficacy. This experiment has an important 
implication: for a given drug, there will be optimal PK properties that produce the shape of 
exposure resulting in most efficient activity. 
   
17-DMAG is a structurally similar benzoquinone to 17-AAG, with increased water solubility 
and increased potency and selectivity for trypanosomes (30). 17-DMAG, like 17-AAG, is 
concentration-driven against trypanosomes. Cmax-intensive (t1/2 1 h) regimens were significantly 
more effective than time-intensive (constant infusion) regimens in the cartridge (Fig. 35A). Both 
17-AAG and 17-DMAG have t1/2s of approximately 1 h in mice (49,104), and were able to cure 
mice of an acute trypanosome infection with Q24 h dosing (30). The Cmax-driven activity 
observed in the cartridge provides rationale for the efficacy of once daily dosing in mice. These 
results show that a single dose with a t1/2 1 h within the 24 h dosing interval would be more 
efficacious than delivering the drug in alternative methods to maintain levels above a threshold.  
 
The intrinsic PK driver was identified for a further two Hsp90 inhibitors from very different 
chemical classes. The resorcinol NVP-AUY922 was chosen due to its experience in the clinic 
(24), and the purine CUDC-305 chosen for its reported blood-brain barrier penetration (a 
requirement for second-stage trypanosomiasis drugs) (42). Both Hsp90 inhibitors were 
concentration-drive. For the same AUC dosed in the contrasting ways of a constant infusion or 
as a Cmax with t1/2 1 h, the Cmax-intensive regimen was significantly more efficacious (Fig. 35). The 
benzoquinone ansamycins, resorcinols, and the purines all bind in the ATP binding pocket of 
Hsp90 (24). The shared driver observed with compounds from all three chemical scaffolds may 
suggest a class-wide PK driver of Hsp90 inhibitor anti-trypanosomal activity, as defined by the 
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target not chemical structure. If there is development of inhibitors specific for HSP83 (Hsp90), 
then they too may be concentration-driven. This knowledge provides rationale for target PK 
properties of specific inhibitors. To generate high peak concentrations that are rapidly cleared, 
prompt and efficient absorption is vital for oral formulations, and short half-lives are preferred 
over long half-lives. Moreover, this class wide PK driver of Hsp90 inhibitor activity against 
trypanosomes can be used to assess in vivo dosing regimens for repurposing the Hsp90 
inhibitors with clinical experience.  
 
17-AAG, 17-DMAG, NVP-AUY922, and CUDC-305 have all been in human trials for 
oncology. Their concentration driven activity against trypanosomes suggests that intermittent 
dosing regimens obtaining high peak levels will be optimal for treating trypanosomiasis. 17-AAG 
has a relatively short half-life of 3 – 5 h in plasma (105), which according to cartridge results is a 
good match for antitrypanosomal activity. Unfortunately, not as good a match for their 
concentration-dependence, CUDC-305 has a longer half-life of 10-20 h (106), and 17-DMAG 
and NVP-AUY922 have terminal t1/2s of 20 and 60 h respectively (102,107). 17-AAG, 17-
DMAG, and NVP-AUY922 all have nanomolar potencies against trypanosomes, and their 
maximally tolerated doses in oncology trials give Cmax and AUCs in plasma in the micromolar 
range, well above what is needed for trypanosomal activity whether dosing is time- or 
concentration-intensive. Specifically, in oncology trials, the MTD of 17-AAG is 300-450 mg/m2 
(once weekly) giving Cmax 15 M and AUC 50 M•h (105,108), the MTD of 17-DMAG is  20 
mg/m2 (twice weekly) giving Cmax 1 M and AUC 4 M•h (102,109), and the MTD of NVP-
AUY922 is 70 mg/m2 (once weekly) giving Cmax 3 M and AUC 30 M•h (107), in plasma. In 
second stage disease, trypanosomes cross the blood-brain barrier in humans. In mice, 17-AAG 
and 17-DMAG do enter the brain, achieving a Cmax one third and one tenth that of plasma, and a 
total AUC one half and equal to that of plasma, respectively (49,104). If this is also the case in 
humans, 17-AAG and 17-DMAG, given their potency, may be able to achieve sufficiently high 
concentrations in the brain to be effective against second-stage HAT; however, differential 
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protein binding in tissue versus plasma may impact the AUC achieved in brain interstitial fluid. 
Although the long half-life of 17-DMAG is not ideal for its use as an antitrypanosomal, it does 
have the highly desirable property of being orally bioavailable (in mice, 50%) (49). CUDC-305 is 
also orally bioavailable, and impressively in mice achieves a four-fold higher AUC in brain than in 
plasma (42). In favor of its optimal antitrypanosomal PK shape, in mice it is cleared faster from 
the brain than plasma (4 vs 8 h half-life), and also cleared rapidly from tissues (2 h half-life in 
liver) (42). Unfortunately, it is not highly potent against trypanosomes, with an EC50 of 3 M in 
cytotoxicity assays. In human oncology phase I trials, the MTD for daily dosing was 1000 mg, 
which led to a plasma Cmax of 0.5 M for parent, and 2 M for the active demethylated 
metabolite, not promising for antitrypanosomal indications (106). More encouragingly the 
incidence of grade 3 adverse events (notably asthenia) decreased with dosing every second day. If 
the brain exposures in humans are similarly larger, and with a faster clearance than plasma, as in 
mice, then CUDC-305 may just have potential activity for second-stage HAT. However, large 
amounts of drug would need to be given. This is not without precedent in trypanosomes, DFMO 
is clinically used for second-stage HAT and has an EC50 of 20 M in vitro and is given in large 
gram quantities in humans (110).  
 
Pharmacokinetic-pharmacodynamic relationships not only apply to desired drug activities, 
but also to undesirable toxicities. One concern with the ansamycin Hsp90 inhibitors is their 
hepatotoxicity, caused by the benzoquinone moiety (111). Intriguingly, hepatotoxicity was the 
major adverse event seen in 17-AAG clinical trials when dosing favored a time-intensive 
exposure, given once daily, and was not a major toxicity when dosed twice or once weekly 
(101,105). This time-driven toxicity is in contrast to concentration-driven activity against 
trypanosomes. A second toxicity seen with Hsp90 inhibitors is vision disturbance, in particular 
night blindness. This has been most frequently observed with 17-DMAG and NVP-AUY922 
(102,107), and not seen with 17-AAG or the resorcinol STA-9090 (112). In a rat study of retinal 
damage from Hsp90 inhibitors, this difference in toxicity was correlated with the clearance of 
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these inhibitors from the retina, as 17-DMAG and NVP-AUY922 had a much longer retention 
(112). This may suggest, that like 17-AAG hepatotoxicity, this is a time-driven effect. Hsp90 
inhibitors with PK properties that lead to high peak concentrations that are rapidly cleared will 
optimize activity against trypanosomes, and may minimize undesired toxicities.  
 
With the many Hsp90 inhibitors that have been in clinical trials or developed by academia 
and industry, there are several potential compounds that may have optimal PK properties for 
antitrypanosomal use. For example, the clinically tested resorcinols STA-9090 and KW-2478 
have half-lives of 7.5 and 6 h respectively (113,114), shorter than that of NVP-AUY922. The 
purine based Hsp90 inhibitor BIIB021 and its metabolites have half-lives of just 0.5 – 2 h, which 
would provide Cmax-intensive exposures (115). NVP-BEP800 is a potent Hsp90 inhibitor 
developed from fragment based screening and has a novel scaffold, with a 2-
aminotheinopyrimidine (116). Pre-clinical data in mice show oral bioavailability, brain penetration 
(concentrations are one fifth to one tenth that of plasma), and rapid clearance from plasma, liver, 
and brain (t1/2 1-3h) (116). Understanding the optimal PK shape of Hsp90 inhibitors for optimal 
PD against trypanosomes provides a valuable criterion for judging potential candidates. 
 
PK-PD relationships are an essential part of understanding the activity of a drug, and the 
optimal way to utilize it. Hsp90 inhibitors have shown promising activity against protozoan 
parasites, including T. brucei, with the ability to cure in vivo model infections. Using in vitro PK-
PD with artificial PK conditions, Hsp90 inhibitors from each of the three major chemical classes 
all had concentration-driven activity against T. brucei. The Hsp90 inhibitors are more efficiently 
dosed against trypanosomes by transient high peak concentrations than by constant levels above 
a threshold. This provides parameters for ideal pharmacological properties for future 
development of specific HSP83 inhibitors. It also provides valuable rationale to assess the 
feasibility of repurposing clinically used Hsp90 inhibitors and to design dosing regimens with the 
greatest likelihood of success against HAT.   
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CHAPTER IV. Shape of the concentration-time curve drives potency: in 
vitro study of antitrypanosomal pharmacokinetic-pharmacodynamics 
 
INTRODUCTION 
T. brucei is an extracellular flagellated and highly motile single-celled eukaryotic parasite 
spread by the tsetse fly vector in sub-Saharan Africa, subspecies of which cause human African 
trypanosomiasis (sleeping sickness). In early disease parasites infect the periphery, then 
subsequently invade the CNS, causing fatality if untreated (2). Epidemics in the early twentieth 
century killed an estimated 800,000 people before pioneering drug discovery efforts produced 
several antitrypanosomals, among the very first of the anti-infective drugs (1). Suramin, 
pentamidine, and melarsoprol, all introduced between 1920 and 1950, remain in use (chemical 
structures of antitrypanosomals, Fig. 36). All three require lengthy courses of injections and have 
severe toxicities. The trivalent organic arsenical melarsoprol is particularly toxic, causing a fatal 
encephalopathy in 2-10% of recipients. Until the 1980s it was the best drug available to treat 
CNS disease. Despite its requirement for a lengthy dosing schedule, DFMO was repurposed  
 
 




from the cancer field and has largely replaced melarsoprol for late-stage west African infections. 
DFMO is ineffective against east African CNS disease, where melarsoprol remains the only 
option. In recent years concerted efforts to develop new treatments have resulted in two 
compounds in clinical trials. Fexinidazole is a nitro-heterocycle nearing completion of Phase 
II/III evaluation and benzoxaborole SCYX-7158 is in Phase I studies (117).  
 
An in vitro hollow fiber cartridge system and experimental method to reveal the 
pharmacokinetic (PK) drivers of antitrypanosomal drugs was developed (Chapter III). Total 
exposure to a drug reflects both concentration and time. A given exposure can be achieved with 
very different concentration-time curves. For a given drug there is a preferred shape to that 
curve, where best efficacy is achieved with least total exposure. Understanding the preferred 
shape allows efficient and effective drug development, and provides a rational basis for dosing 
regimens in humans. The in vitro hollow fiber system and method was used to explore 
pharmacokinetic-pharmacodynamic (PK-PD) relationships for several classic antitrypanosomals 
and current clinical candidates. Dynamic in vitro PK-PD has not previously been explored for 
these agents. Knowledge of PK governance provides a rational basis for assessing and improving 
their dosing regimens.  
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MATERIALS AND METHODS 
Cell Culture and Reagents. Bloodstream form T. b. brucei (MiTat 1.2 strain 427) was maintained 
in log growth at 37°C, 5% CO2 in phenol red-free HMI9, 10% FBS, 10% Serum Plus (Sigma). 
Motile cells were counted by hemocytometer and light microscope. Drug stocks were stored 
aliquoted (-20°C): suramin (Mobay Chemical Corp.), pentamidine (American Pharmaceutical 
Partners), D,L-DFMO (National Cancer Institute (NCI) Developmental Therapeutics Program) 
in water; melarsoprol (Centers for Disease Control and Prevention) in 1,2-propanediol; SCYX-
7158, fexinidazole (and sulfone), in DMSO. Using published methods (118-121) fexinidazole, 
fexinidazole sulfone, and SCYX-7158 were synthesized (Appendix). Tracers were U[3H]suramin 
(42 Ci/mmol; Moravek) and [14C]pentamidine (32 mCi/mmol; NCI).  
 
Cartridge Assembly, PK Determination, and PK-PD Studies. Methods were as in Chapter 
III. Briefly, reservoirs and platinum-cured silicone tubing were autoclaved then assembled in a 
biosafety cabinet. Non-specific binding was assessed by determining concentration (bioassay or 
cognate radiolabeled tracer) over time of drug in HMI9 incubated in an isolated cartridge (C2025, 
FiberCell Systems) (Table 5). Prior to experiments, cartridges were pre-incubated with drug 
solutions calculated to achieve desired t0 free drug concentrations (Table 5). Reservoirs, tubing, 
and cartridges were then filled with t0 solutions, and flow rate set to 0.45 mL/min (IPC, Ismatec). 
PKs were first determined in the absence of parasites, sampling the extra-fiber space from the 
distal cartridge port. For Cmax regimens, central reservoir volume was iteratively adjusted to 
provide desired t1/2 (within 10% of 1 h; or pentamidine 1.7 h). For the fexinidazole infusion 
regimen, over 24 h a consistent loss of drug in tubing was observed between the infusion input 
reservoir and the cartridge. The reservoir concentration was increased to give the desired infusion 
concentration entering the cartridge. To achieve 20 M, the infusion reservoir was at 66 M to 
account for a 70% loss (Table 5). For PK-PDs, pre-incubation medium in cartridges was replaced 
with 105 cells/mL at t0 drug concentrations, and incubated at 37°C, 5% CO2. The culture used to 
inoculate cartridges was maintained in parallel flasks. Cells were harvested at 24 h and number of 
live parasites in drug-treated cartridges compared to that of untreated control cartridge.  
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Table 5. Antitrypanosomal non-specific binding and conditions to attain desired kinetics 
Drug Drug loss in 
cartridge (%)
a 
  Cartridge pre-incubation
b 




Drug loss in 
tubing (%)
d 
Suramin 50 2 2  25 0 
DFMO 5 - - 30 0 
Melarsoprol 67 3 3 25 0 
Pentamidine 90 10 1 13.5 (t1/2 1.7 h) 0 
SCYX-7158 67 3 1 30 0 
Fexinidazole 90 10 1 13.5 70 
Fexinidazole 
sulfone 
88 8 3 20 0 
a
Drug bound at equilibrium after incubation in an isolated cartridge with high drug concentration 
b
Conditions used for pre-incubation to compensate for nonspecific binding of drug to cartridge. Based on the 
percentage of drug lost, the indicated multiple (x) of the t0 drug concentration was incubated in the cartridge for 
indicated duration before start of experiment 
c
Volume in central reservoir for Cmax regimens to ensure t1/2 of 1 h in extra-fiber space of cartridge 
d
Drug loss between the input reservoir and point of entry into cartridge. Fexinidazole infusion input 
concentrations were increased to account for 70% loss 
 
Drug Cytotoxicity and Concentration Bio-assays. Cytotoxicity assays in 96 well plates used 
an established acid phosphatase-based method (Chapter I)(39). By this method PK samples were 
bioassayed, comparing cytotoxicity of unknowns with a standard curve of drug concentrations. 
 
Time-kill and Reversibility. 2x105 cells/mL in 24-well plates were exposed to 20x EC99 (except 
fexinidazole, 5x EC99) for 6 h then split. One population remained in drug; the other was washed 
thrice in drug-free medium (>4000x drug dilution). Cells were counted by hemocytometer. 
 




Design to Determine Kinetic Driver of Efficacy. PK-PD studies comprised three cartridges: 
one no-drug control and two drug-treated, with efficacy based on counting motile parasites at 24 
h. Starting density of 105 cells/mL resulted in log growth of control cells for 24 h. Cells in the 
treated cartridges had the same total drug exposure (dose, or AUC0-24), deployed as either a 
steady infusion of a constant concentration (“time-intensive”) or as a contrastingly high peak 
concentration with t1/2 1 h (“Cmax-intensive”)(Fig. 37A). Pharmacokinetics of Cmax regimens were 
confirmed in the extra-fiber space of the cartridge for all drugs (Fig. 37B). To diagnose the 
intrinsic PK driver, initially an AUC0-24 was chosen where efficacy of the infusion was in the 
linear dose-response range, typically around 50%. This allowed detection of a positive or negative 
efficacy shift in the comparator Cmax-intensive regimen. The artificial t1/2 1 h yields a 16.8-fold 
greater Cmax than the infusion, and concentration drops by 98% over 6 h, the length of one cell 
cycle of T. brucei (Fig. 37A). The infusion also allowed direct comparison with the same 
concentration in microtiter plate assays (Fig. 38). Suramin, pentamidine, SCYX-7158, and 
fexinidazole sulfone infusions in the cartridge were more effective than the same concentrations 
in plates, DFMO and melarsoprol had equivalent efficacies, and fexinidazole was less effective in  
             
Figure 37. PK of antitrypanosomals in hollow-fiber cartridges 
(A) Two cartridges are exposed to the same AUC0-24 (shaded), but in contrasting regimens as either a 
high peak with t1/2 1h (blue) or as a constant infusion (red). (B) For Cmax regimens actual PKs of 
indicated drugs obtained from the extra-fiber space were assayed in two or more experiments, and 
achieved t1/2 within 10% of 1 h (dotted curve), except pentamidine which achieved and was studied at 




the cartridge. Efficacy in the cartridge may be enhanced by constant provision of fresh drug (two 
hundred-fold greater total mass of drug passed by cells in the cartridge versus in wells), or 
alternatively may be hindered by fresh nutrients and removal of waste. In any case it is likely that 
cartridge conditions more closely mimic those in vivo. 
 
Figure 38. Comparison of efficacy in cartridge versus microtiter plate 
Efficacy relative to no drug control in the cartridge system of constant infusions of drug compared to 
efficacy of the same concentration in microtiter plate assays. Mean±SD, for n ≥ 3. 
 
Suramin Efficacy is Driven by Peak Concentration. Suramin, an antitrypanosomal introduced 
in the 1920s, was examined in the dynamic in vitro PK-PD system. A time-intensive constant 
infusion of 0.3 M over 24 h caused 58% reduction in final cell number compared to drug-free 
controls. The same total AUC0-24 applied as a 5.0 M Cmax with t1/2 1 h resulted in 98% reduction 
(Fig. 39A). Thus, for the same drug exposure, efficacy was nearly doubled by simply changing the 
shape of the AUC to favor peak concentration (Fig. 37A). Suramin is concentration-driven and 
does not require sustained levels for efficacy, a finding that held with human pathogenic 
subspecies T. b. gambiense (Fig. 40). To further investigate PK-PD, a wide AUC0-24 range was 
tested, dosed either with t1/2 1 h or as an infusion, and two complete exposure-response curves 
were generated for these contrasting regimens (Fig. 39B). The linear response range of the curves 
was widely separated, systematically favoring Cmax- over time-intensive dosing. Vertically, for the 
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same AUC, a substantial gain was achieved by Cmax regimens: for example, 85% efficacy at AUC0-
24 5 M•h versus 15% for infusion. Horizontally, suramin was 2-fold more ‘potent’ if applied to 
favor Cmax: EA50 values (AUC0-24 that gives 50% response) were 3.6 M•h for Cmax but 7.2 M•h 
for time. Likewise, and notably, concentration-intensive dosing achieved maximal efficacy with a 
2-fold lower total dose (AUC0-24).   
 
Figure 39. Suramin is more efficacious when dosed to favor high peak concentration. 
(A) Suramin AUC0-24 of 7.2 M•h applied as a high Cmax of 5.0 M with t1/2 1 h (blue) or as a constant 
infusion of 0.30 M (red), ** p<0.01. (B) Exposure-response curves. Suramin was applied as high Cmax 
with t1/2 1 h (blue, EA50 3.7 M•h) or as a constant infusion (red, EA50 7.2 M•h), across a range of 
AUC0-24. Percent effect is reduction at 24 h in trypanosome count compared to untreated control 
cartridge. Mean±SD for n ≥ 3.  
 
Figure 40. Suramin is concentration-driven against T. b. gambiense.  
Reduction in cell number of T. b. gambiense (strain 348 BT) at 24 h for AUC0-24 6 M•h, applied as a 
high Cmax of 4.2 M with t1/2 1 h (blue) or constant infusion of 0.25 M (red). Cells were adapted in 




DFMO Efficacy is Driven by Time of Exposure. DFMO at an AUC0-24 of 2400 M•h was 
76% effective as a time-intensive infusion, but only 55% effective as high Cmax with t1/2 1 h 
(p<0.05, Fig. 41). Thus, in contrast to suramin, the antiparasitic activity of DFMO is time- rather 
than peak concentration-driven. DFMO infusions had an EA50 of 600 M•h versus 1500M•h 
for Cmax dosing (Fig. 41), a 2.5-fold ‘potency’ difference. The exposure-response curves had 
shallow slopes, and for the same AUC0-24 greatest vertical difference in efficacies was 25 points. 
Interestingly this difference was maintained at the maxima, such that Cmax dosing achieved at best 
only a 55% reduction in parasite count, whereas infusion dosing reached 80%. By all measures 
DFMO is most advantageously applied to maintain concentrations over time rather than to favor 
peak concentration, and sustained levels are necessary for maximum effect. 
 
 
Figure 41. DFMO efficacy is time-driven. 
Across three logs of AUC0-24, the efficacy of a time-intensive constant infusion (red, EA50 600 M•h) 
was compared to that of a short-lived high Cmax, t1/2 1 h (blue, EA50 1500 M•h). Percent effect is cell 





Melarsoprol, Pentamidine, SCYX-7158, and Fexinidazole are Concentration-Driven. The 
remaining antitrypanosomals studied were all significantly more efficacious with Cmax-intensive 
dosing rather than time-intensive infusions (Fig. 42). Fexinidazole in vivo is metabolized to a 
sulfoxide and then sulfone, both active. The PK driver of fexinidazole sulfone was tested, which 
as for parent fexinidazole was concentration-driven (Fig. 42), consistent with the class-wide 




Figure 42. Melarsoprol, pentamidine, SCYX-7158, fexinidazole, and fexinidazole sulfone are 
concentration-driven. 
A given AUC0-24 was applied as a transient high concentration (blue) or as a constant infusion (red). 
Unless indicated otherwise, t1/2 1 h for Cmax regimens. Conditions were (AUC0-24; Cmax, Infusion): 
melarsoprol (310 nM•h; 220 nM, 13 nM), pentamidine (53 nM•h; 22 nM t1/2 1.7 h, 2.2 nM), SCYX-
7158 (24 M•h; 17 M, 1 M), fexinidazole (480 M•h; 336 M, 20 M), and fexinidazole sulfone 
(110 M•h; 80 M, 4.8 M). Percent effect is cell count reduction versus controls. Mean±SD, n ≥ 3; * 
p<0.05, ** p<0.01.  
 
 
Time-kill and Reversibility of Drug Action. As Cmax regimens have relatively transient drug 
levels, concentration-driven compounds likely rapidly initiate cell-killing, or have a significant 
post-antiparasitic effect. To assess some of these factors trypanosomes were exposed in plates to 
drug, with either wash-out at 6 h or maintained presence, and cell viability determined over 48 h 
by counting motile cells. Concentrations were high, 20-times the microtiter plate EC99 (~peak 
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concentration of an equivalent Cmax cartridge regimen), and reversibility was analyzed after 6 h 
(one doubling time). (Fexinidazole was just 5-times the EC99 due to solubility limits.)  
 
Each drug had a distinctive time-effect profile, with different rates of growth inhibition, cell 
killing, and post-drug effect (Fig. 43). Melarsoprol, fexinidazole sulfone, SCYX-7158, 
pentamidine, and suramin (in order of onset time and log kill rate) were all cytocidal (‘cidal) at 
these exposures, causing a progressive fall in cell number whether drug concentrations were 
sustained for 48 h or pulsed for 6 h then chased for 42 h. Both pentamidine and suramin 
exhibited delayed death effects. In contrast, fexinidazole and DFMO were cytostatic (‘static): 
growth resumed after drug was washed away. In 10 mM DFMO onset of action was slow, with 
trypanosomes continuing to increase for 12 h, then stopping, but not declining. Fexinidazole 
caused immediate arrest and if maintained cell numbers slowly declined; on wash-out at 6 h there 
were several further hours of post-antiparasitic effect before growth resumed at 10 h. 
 
 
Figure 43. Time-kill and reversibility of antitrypanosomals. 
Trypanosomes were exposed to high concentrations of the indicated drugs, either continuously (solid 
lines) or for a 6 h period then washed (shaded grey interval, dotted lines). Motile cells were counted 




In order to identify the intrinsic PK driver of drug efficacy sharply contrasting shapes of 
exposure were generated with artificial kinetics. By plotting AUC-response curves based on the 
shape of exposure delivered (Fig. 39B and Fig. 41) information was captured that is unattainable 
through conventional in vitro assays, and not readily obtained in vivo. The results were highly 
informative. Shape of the AUC determines ‘potency’ and efficacy, with clear separation between 
the response curves of Cmax- or time-intensive regimens. Suramin and DFMO were governed by 
opposite drivers, and their curves had various slopes and separations, suggesting that each drug is 
uniquely affected by shape of exposure changes. Vertical separation of AUC-response curves 
highlights the efficacy that is gained from an optimally shaped exposure. Horizontal separation 
reflects differences in potency: the exposure required for equi-efficacy. Importantly, maximal 
efficacy is achieved with lower total AUC when the PK driver is favored. In fact, time-intensive 
dosing was necessary for DFMO to achieve maximal efficacy. Cmax-dosing yielded a lower 
efficacy plateau, perhaps reflecting DFMO’s static nature and inability to eradicate parasites (Fig. 
41 and Fig. 43). The AUC-response curves reveal that each drug has intrinsic PK-PD 
governance, a fundamental kinetic driver of antitrypanosomal activity, and therefore ideal PK 
properties for optimal potency and efficacy.  
 
Melarsoprol, pentamidine, SCYX-7158, and fexinidazole all had greater activity deployed as a 
high Cmax regimen (Fig. 42). Though most of these drugs were ‘cidal, fexinidazole had ‘static 
activity (Fig. 43), demonstrating that concentration- or time-driven efficacy does not equate with 
‘cidal or ‘static activity, as is recognized for antibacterials (90). As Cmax regimens in the cartridge 
incorporate immediate, delayed, and post-drug effects, fexinidazole's Cmax governance may reflect 
the early onset arrest and then significant post-antiparasitic delay in cell growth (Fig. 43). 
Interestingly fexinidazole sulfone, like parent, was concentration-driven, but unlike parent it was 
‘cidal (Fig. 42 and Fig. 43). The PK driver of a drug is an empirical description that captures the 
sum of multiple factors. For all drugs studied a significant separation between the efficacies of 
Cmax- or time- intensive regimens was observed (Fig. 39-41); however, the degree of separation 
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differed, and it is possible that for some drugs there would be insignificant separation. Testing a 
single AUC in the two contrasting ways allows efficient diagnosis of the preferred kinetic driver, 
and full exposure-response curves provide even greater insight.  
 
These findings have important inferences for drug development and clinical use. In vitro 
PK-PD is particularly valuable for trypanosomes, as resource-limited remote settings and invasive 
diagnostic procedures make human studies unusually challenging. In early-stage drug 
development knowledge of the intrinsic PK driver can inform lead candidate choice and PK 
property optimization. In vivo, although the complexity of living systems (tissue specific PK, 
protein binding, and immune effects, for example) will change the absolute values of 
concentration and AUC required for efficacy, knowing the optimal shape of exposure is a simple 
and powerful guide for assessing a dosing regimen. Time-dependency predicts that 
concentrations must be sustained for best efficacy in vivo, whereas concentration-driven efficacy 
predicts intermittent dosing achieving high peaks will be optimal.  
 
DFMO was the only time-driven drug, and reported results from in vivo studies support this 
finding. In mice, multiple day dosing of DFMO in the drinking water is required for cure 
(122,123). The inopportune 3.5 h half-life of DFMO in humans requires frequent dosing to 
maintain concentrations (124), and efforts to dose every 12 h instead of 6 h resulted in greater 
frequency of relapse (125). DFMO is now most commonly given every 12 h in combination with 
nifurtimox. Clinical trials have demonstrated non-inferiority of this combination to monotherapy 
(126); however, given the in vitro findings that DFMO resistance can be selected by exposure to 
low DFMO concentrations and that nifurtimox and DFMO are antagonistic (127), time-driven 
efficacy suggests a return to dosing DFMO every 6 h in the combination may lower the risk of 





The classic drugs, suramin, pentamidine, and melarsoprol, were originally established with 
lengthy dosing regimens and little PK-PD knowledge. The need to optimize and shorten these 
regimens is recognized (110). These results of concentration-driven efficacy provide rationale for 
this, and are supported by in vivo evidence. A single dose of each of these drugs can be curative 
in mice, and clear trypanosomes from human body fluids, indicating long exposures are not 
necessary for activity (3,128-130). In T. b. gambiense-infected guinea pigs, single dose pentamidine 
(5 mg/kg) was curative, but when split into ten twice weekly doses animals relapsed (129). Early 
investigators of suramin and melarsoprol concluded initial large doses were the most important 
determinant of efficacy and potentially sufficient for cure in humans (131-133). As suramin and 
pentamidine are effective against early-stage infection, concentration-driven efficacy suggests 
their activity in blood may stem from the peak of their biphasic distributions (134,135). 
Melarsoprol however is used against CNS infection, so concentration-driven efficacy would 
predict high peaks in that compartment would enhance efficacy. Melarsoprol’s regimen has 
already been revised to just 10 consecutive daily doses (136); from our findings this might be 
improved further by administering fewer but larger doses. Melarsoprol toxicity, an important 
concern, will also have a PK-PD component. Intriguingly, doubling the starting dose from 1.8 to 
3.6 mg/kg decreased the incidence of reactive encephalopathy (137), and in a leukemia trial 
neurotoxicity was only seen in the second week of injections, perhaps a time-driven effect (8). In 
any optimization of dosing, the PK-PD relationship for efficacy must be balanced with those for 
toxicities, and when possible discrepant drivers should be exploited to favor efficacy and 
minimize side-effects. 
 
Oxaborole SCYX-7158 is in early clinical development. In the cartridge it was optimally 
dosed by Cmax-intensive regimens (Fig. 42). This seems inconsistent with previous in vitro results 
that an AUC 41 M•h given as 1.7M for 24 h was irreversible (at 72 h), whereas the same AUC 
as 6.8 M for 6 h was reversible (138,139). However, higher concentrations of SCYX-7158 can 
be ‘cidal on exposures of 6 h or less (Fig. 43)(138). In the cartridge an AUC0-24 of just 24 M•h 
distributed as a 17 M peak with t1/2 1 h caused maximal effect (Fig. 42). This highlights the 
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importance of studying dynamic AUC shapes. SCYX-7158 has been tested in mouse models of 
early- and late-stage trypanosomiasis. Its 26 h plasma half-life makes it impossible to restructure 
the AUC in vivo so as to generate high peaks that are rapidly cleared (138). However, in mouse 
brain tissue the half-life is closer to 4 h (139). In Phase I trials SCYX-7158 had a 16 day plasma 
half-life in humans, again making short-lived peaks impossible (117). However, if CNS half-lives 
are substantially shorter as in rodents, cartridge results suggest achieving early high 
concentrations in the CNS will lead to clinical success.  
 
Fexinidazole is efficacious in early- and late-stage murine models, and has progressed to 
Phase II/III trials (117,140-142). Both parent and active sulfone metabolite are concentration-
driven (Fig. 42). Consonant with this finding, despite the short half-lives (≤2 h) of fexinidazole 
and its metabolites in mouse plasma (and likely similar in brain), in the mouse chronic infection 
model once-daily dosing with 200 mg/kg achieves greater cures than twice-daily dosing with 100 
mg/kg (141,142). In humans plasma half-lives are longer, on the order of 10 h for fexinidazole 
and sulfoxide, and 25 h for the subsequent sulfone (140). The Phase II/III clinical trial assessing 
once daily doses relies on accumulation of, and sustained exposure to, the sulfone (simulated in 
Fig. 44)(140). Unfortunately, in mice the sulfone is the least brain-penetrant of the three moieties 
(141). Given the cartridge finding that high peaks are more effective than sustained levels, the 
regimen may better be deployed as larger doses on intermittent and fewer days, if tolerability 
allows. This would optimize the shape of exposure and resulting efficacy of all three compounds 






Figure 44. Simulations of alternative fexinidazole dosing regimens. 
To generate higher peaks of all three metabolites the same total dose used in the Phase II/III regimen 
could be restructured as larger doses on intermittent days. As absorption is dose-limiting, the larger 
dose would need to be split over several administrations, here hypothetically given in 4 h intervals. 
These simulations illustrate how dose schedule can modify the shape of exposure, and are not 
intended as clinical recommendations. Simulations performed in Excel using approximate tmax, Cmax, 
and t1/2 values from Phase I study data (140) as follows: 1800 mg dose fexinidazole (4 h, 5.4 M, 11 h), 
sulfoxide (4 h, 26 M, 12 h), sulfone (24 h, 32 M, 25 h); 1200 mg dose fexinidazole (4 h, 3.2 M, 11 
h), sulfoxide (4 h, 16 M, 12 h), sulfone (24 h, 19 M, 25 h). (A) Simulation of Phase II/III regimen of 
1800 mg per day for four days, followed by 1200 mg per day for six days, total dose 14,400 mg. Open 
circles, reported Cmax values (140). (B) Simulation of 1200 mg at 0, 4, and 8 h on Day 0, 2, 4, and 6, 
total dose 14,400 mg. (C) Simulation of 1200 mg at 0, 4, 8, and 12 h on Day 0, 3, and 6, total dose 
14,400 mg. (D) Simulation of 1800 mg at 0, 4, and 8 h on Day 0, 3, and 6, total dose 16,200 mg. (E) 
Simulation of 1800 mg at 0, 4, 8, and 12 h on Day 0 and 4, total dose 14,400 mg.  
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 Shape of the concentration-time curve is a critical determinant of antitrypanosomal efficacy. 
Clearly demonstrated by plotting exposure-response curves, maximal effect will be achieved with 
the least total drug exposure when the shape of the PK profile favors a drug’s driver. 
Concentration- or time-driven efficacy is a useful simplification of a complex multidimensional 
relationship. The findings with five clinical, and two candidate, antitrypanosomals are consistent 
with reported in vivo results. This in vitro methodology is efficient, convenient, and versatile, 
particularly valuable for the resource-limited and clinically challenging field of antitrypanosomal 
chemotherapy. These concepts and approaches are likely also relevant for other therapeutic 
indications. In drug development, knowledge of the PK-PD governance can be used as selection 
criterion for leads and to direct development such that in vivo PK properties are matched with 
efficacy driver. Dynamic in vitro PK-PD is a powerful tool that can inform all stages of drug 








This thesis details investigation into the pharmacology of Hsp90 inhibitors against T. brucei. 
Potent in vitro growth inhibition was discovered (Chapter I), and in particular disruption to both 
cytokinesis and kDNA replication (Chapter II). Phenotypes observed with RNAi knock-down of 
the trypanosome HSP83 and putative mitochondrial TbTRAP were similar to the cell cycle 
aberrations seen with Hsp90 inhibitor treatment, validating target suppositions (Chapter II). To 
investigate dosing requirements, an in vitro PK-PD system was established for T. brucei (Chapter 
III and IV). Hsp90 inhibitors were significantly more efficacious against trypanosomes when 
dosed as transient high peaks rather than as prolonged lower concentrations (Chapter III), 
implying that long half-lives are not required for efficacy in vivo and that intermittent dosing 
regimens should be efficacious and in fact optimal. Intermittent once daily dosing of the short-
lived inhibitor 17-DMAG was efficacious and able to cure mouse trypanosomiasis, including 
when dosed orally (Fig. 8).  
   
The promising results with Hsp90 inhibitors provide further proof that repurposing 
oncology drugs is a viable drug development strategy for T. brucei. Despite a homologous target, a 
therapeutic index is possible due to divergent cell biology. RNAi results of disrupted cleavage 
furrow ingression and kDNA replication provide evidence of how within the unique context of 
the trypanosome inhibiting HSP83 has unique effects (Chapter II). Several groups have reported 
activity of Hsp90 inhibitors against protozoan parasites (143), and this work provides valuable 
supportive evidence that Hsp90 inhibitors can be effective anti-protozoals. Furthermore, novel 
insight has been gained of the roles of T. brucei HSP83 and putative mitochondrial TbTRAP.    
 
Ultimately, therapeutic index is a question of dosing. In vivo, drug exposures are not static 
but have a dynamic concentration-time profile. For trypanosomes resource-limited remote 
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settings and invasive diagnostic procedures make human studies unusually challenging (1), 
therefore in vitro methods to study PK-PD are particularly valuable. A method to study 
dynamically changing concentration-time profiles against trypanosomes in vitro was developed. 
Several challenges were overcome, namely balancing robust growth of parasites with tractable 
PK. Shape of the drug exposure was demonstrated to be a vital determinant of antitrypanosomal 
efficacy. Conventionally, PK-PD is considered late in the drug development pathway after a drug 
has been introduced in vivo. In the antibiotic and antiviral field, in vitro PK-PD is increasingly 
recognized as an important contribution; however, PK-PD is simply used to model in vivo half-
lives and predict clinical targets (28,29). In this thesis, artificial kinetics were employed and 
highlighted the fact that compounds have intrinsic drivers of efficacy, and therefore a certain 
shape of exposure which will allow maximal response for the least total exposure (Chapter III 
and IV). Both concentration and duration of drug exposure need to be considered as dynamic 
variables. The discrimination of compounds as either concentration- or time-driven as detailed in 
this thesis has important implications for target product profiles of lead candidates. Conventional 
methods used to investigate drug efficacy would be much enhanced by considering in vitro PK-
PD from the earliest stages of drug development. 
 
Hsp90 inhibitors were significantly more efficacious dosed in concentration-intensive rather 
than time-intensive exposures against trypanosomes, as were three of the clinically used 
antitrypanosomals and two current clinical candidates (Chapter III and IV). Importantly DFMO 
was found to be time-driven (Fig. 41). For 17-AAG, suramin, and DFMO the shape and 
magnitude of separation between delineated concentration- vs time-intensive exposure-response 
curves differed, revealing each drug has unique response to changes in shape of exposure 
(Chapter III and IV). Concentration- or time-driven efficacy is a useful simplification of the 
complex PK-PD multidimensional response-surface. What determines whether a drug will be 
concentration- or time-driven? Presumably it is some interplay between the kinetics of target 
inactivation and down-stream consequences in the cell. For DFMO, rapid reversibility of growth 
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inhibition on drug removal is likely the reason for time-driven efficacy (Fig. 43). Concentration-
driven drugs in contrast likely initiate irreversible damage or have significant post-drug effects, as 
the drug effect outlasts the presence of the drug. For the Hsp90 inhibitors, even short exposures 
cause significant disruption of down-stream clients and pathways as evidenced by cell cycle 
lesions (Chapter II). As 9 out of the 10 drugs tested were concentration-driven, trypanosomes 
seem particularly prone to irreversible damage, likely due to the lack of cell cycle checkpoints and 
therefore insufficient time and resources to fully repair injury (19).   
 
In vitro PK-PD results suggest that Hsp90 inhibitors with fast absorption rates and short 
half-lives in vivo will be ideal for antitrypanosomal use. Dosing regimens do not need to maintain 
drug levels, but rather achieve sufficient peaks. However, mouse results with 17-DMAG 
demonstrate that concentration-driven activity does not necessarily mean single dose cure (Fig. 
8). Toxicity, always a vital consideration in drug dosing, may limit the AUC achievable with a 
single dose and pharmacological sanctuaries in tissues may enable trypanosomes to escape the 
peak of drug. Within a dosing interval concentration-intensive exposures will be the most 
efficacious, but repeated dosing may still be necessary for radical cure. 17-DMAG, despite a short 
t1/2 of 1 h, was able to achieve cures with once daily multiple day dosing both intraperitoneally 
and orally. 
 
In summary, this thesis research has enhanced understanding of T. brucei Hsp90s and the 
potential for use of Hsp90 inhibitors against trypanosomes. The development of an in vitro PK-
PD system to study antitrypanosomals allows a greater understanding of efficacy and enhances 






Alignment of HSP83 coding sequences 
Tb927.10.10890/10900/10910/10920/10930/10940/10950/10960/10970/10980 (69). 
Synonymous variations highlighted in green, nonsynonymous variations highlighted in yellow, 
RNAi sequence in red  
 
CLUSTAL O(1.2.1) multiple sequence alignment 
 
Tb...10930      ATGACGGAGACATTCGCATTCCAGGCTGAAATCAATCAGCTAATGTCCCTTATTATTAAT   60 
Tb...10970      ATGACGGAGACATTCGCATTCCAGGCTGAAATCAATCAGCTAATGTCCCTTATTATTAAT   60 
Tb...10980      ATGACGGAGACATTCGCATTCCAGGCTGAAATCAATCAGCTAATGTCCCTTATTATTAAT   60 
Tb...10960      ATGACGGAGACATTCGCATTCCAGGCTGAAATCAATCAGCTAATGTCCCTTATTATTAAT   60 
Tb...10950      ATGACGGAGACATTCGCATTCCAGGCTGAAATCAATCAGCTAATGTCCCTTATTATTAAT   60 
Tb...10940      ATGACGGAGACATTCGCATTCCAGGCTGAAATCAATCAGCTAATGTCCCTTATTATTAAT   60 
Tb...10910      ATGACGGAGACATTCGCATTCCAGGCTGAAATCAATCAGCTAATGTCCCTTATTATTAAT   60 
Tb...10920      ATGACGGAGACATTCGCATTCCAGGCTGAAATCAATCAGCTAATGTCCCTTATTATTAAT   60 
Tb...10900      ATGACGGAGACATTCGCATTCCAGGCTGAAATCAATCAGCTAATGTCCCTTATTATTAAT   60 
Tb...10890      ATGACGGAGACATTCGCATTCCAGGCTGAAATCAATCAGCTAATGTCCCTTATTATTAAT   60 
                ************************************************************ 
 
Tb...10930      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG   120 
Tb...10970      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG   120 
Tb...10980      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG   120 
Tb...10960      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG   120 
Tb...10950      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG   120 
Tb...10940      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG   120 
Tb...10910      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG   120 
Tb...10920      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG   120 
Tb...10900      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG   120 
Tb...10890      ACCTTCTATTCAAACAAGGAAATTTTTCTTCGCGAGCTAATTAGTAATTCGTCAGATGCG   120 
                ************************************************************ 
 
Tb...10930      TGCGACAAAATCCGGTACCAGAGTCTGACGAGCCAGTCCGTGCTCGGAGATGAACCCCAT   180 
Tb...10970      TGCGACAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT   180 
Tb...10980      TGCGACAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT   180 
Tb...10960      TGCGACAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT   180 
Tb...10950      TGCGACAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT   180 
Tb...10940      TGCGACAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT   180 
Tb...10910      TGCGACAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT   180 
Tb...10920      TGCGACAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT   180 
Tb...10900      TGCGACAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT   180 
Tb...10890      TGCGACAAAATCCGGTACCAGAGTCTGACGAACCAGTCCGTGCTCGGAGATGAACCCCAT   180  
                ******************************* **************************** 
 
Tb...10930      TTGCGCATTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGGC   240 
Tb...10970      TTGCGCATTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGGC   240 
Tb...10980      TTGCGCATTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGGC   240 
Tb...10960      TTGCGCATTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGGC   240 
Tb...10950      TTGCGCATTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGGC   240 
Tb...10940      TTGCGCATTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGGC   240 
Tb...10910      TTGCGCATTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGGC   240 
Tb...10920      TTGCGCATTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGGC   240 
Tb...10900      TTGCGCATTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGGC   240 
Tb...10890      TTGCGCATTCGCGTAATCCCCGACCGAGTAAATAAGACACTGACGGTGGAGGACAGTGGC   240  
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                ************************************************************ 
 
Tb...10930      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC   300 
Tb...10970      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC   300 
Tb...10980      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC   300 
Tb...10960      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC   300 
Tb...10950      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC   300 
Tb...10940      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC   300 
Tb...10910      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC   300 
Tb...10920      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC   300 
Tb...10900      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC   300 
Tb...10890      ATCGGTATGACGAAAGCCGACCTGGTGAACAACCTTGGTACGATTGCTCGCTCCGGTACC   300  
                ************************************************************ 
 
Tb...10930      AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC   360 
Tb...10970      AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC   360 
Tb...10980      AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC   360 
Tb...10960      AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC   360 
Tb...10950      AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC   360 
Tb...10940      AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC   360 
Tb...10910      AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC   360 
Tb...10920      AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC   360 
Tb...10900      AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC   360 
Tb...10890      AAGTCATTCATGGAGGCATTGGAGGCCGGTGGCGATATGAGCATGATCGGGCAGTTCGGC   360  
                ************************************************************ 
 
Tb...10930      GTCGGATTTTACTCTGCCTACCTTGTCGCAGACCGCGTAACCGTTGTGTCGAAGAACAAC   420 
Tb...10970      GTCGGATTTTACTCTGCCTACCTTGTCGCAGACCGCGTAACCGTTGTGTCGAAGAACAAC   420 
Tb...10980      GTCGGATTTTACTCTGCCTACCTTGTCGCAGACCGCGTAACCGTTGTGTCGAAGAACAAC   420 
Tb...10960      GTCGGATTTTACTCTGCCTACCTTGTCGCAGACCGCGTAACCGTTGTGTCGAAGAACAAC   420 
Tb...10950      GTCGGATTTTACTCTGCCTACCTTGTCGCAGACCGCGTAACCGTTGTGTCGAAGAACAAC   420 
Tb...10940      GTCGGATTTTACTCTGCCTACCTTGTCGCAGACCGCGTAACCGTTGTGTCGAAGAACAAC   420 
Tb...10910      GTCGGATTTTACTCTGCCTACCTTGTCGCAGACCGCGTAACCGTTGTGTCGAAGAACAAC   420 
Tb...10920      GTCGGATTTTACTCTGCCTACCTTGTCGCAGACCGCGTAACCGTTGTGTCGAAGAACAAC   420 
Tb...10900      GTCGGATTTTACTCTGCCTACCTTGTCGCAGACCGCGTAACCGTTGTGTCGAAGAACAAC   420 
Tb...10890      GTCGGATTTTACTCTGCCTACCTTGTCGCAGACCGCGTAACCGTTGTGTCGAAGAACAAC   420  
                ************************************************************ 
 
Tb...10930      GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG   480 
Tb...10970      GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG   480 
Tb...10980      GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG   480 
Tb...10960      GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG   480 
Tb...10950      GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG   480 
Tb...10940      GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG   480 
Tb...10910      GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG   480 
Tb...10920      GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG   480 
Tb...10900      GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG   480 
Tb...10890      GAGGACGATGCCTACACGTGGGAATCCTCTGCAGGTGGTACCTTCACTGTAACCTCCACG   480  
                ************************************************************ 
 
Tb...10930      CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG   540 
Tb...10970      CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG   540 
Tb...10980      CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG   540 
Tb...10960      CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG   540 
Tb...10950      CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG   540 
Tb...10940      CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG   540 
Tb...10910      CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG   540 
Tb...10920      CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG   540 
Tb...10900      CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG   540 
Tb...10890      CCCGACTGTGACCTGAAGCGCGGTACGCGTATCGTCTTGCATTTGAAGGAAGACCAGCAG   540  
                ************************************************************ 
 
Tb...10930      GAATACCTGGAGGAGCGGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC   600 
Tb...10970      GAATACCTGGAGGAGCGGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC   600 
Tb...10980      GAATACCTGGAGGAGCGGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC   600 
Tb...10960      GAATACCTGGAGGAGCGGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC   600 
Tb...10950      GAATACCTGGAGGAGCGGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC   600 
Tb...10940      GAATACCTGGAGGAGCGGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC   600 
Tb...10910      GAATACCTGGAGGAGCGGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC   600 
Tb...10920      GAATACCTGGAGGAGCGGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC   600 
Tb...10900      GAATACCTGGAGGAGCGGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC   600 
Tb...10890      GAATACCTGGAGGAGCGGCGGCTGAAGGACCTCATCAAAAAACACTCCGAATTTATCGGC   600  
                ************************************************************ 
 
Tb...10930      TACGACATCGAGTTAATGGTGGAGAACACCACTGAGAAGGAGGTGACAGATGAAGACGAA   660 
Tb...10970      TACGACATCGAGTTAATGGTGGAGAACACCACTGAGAAGGAGGTGACAGATGAAGACGAA   660 
Tb...10980      TACGACATCGAGTTAATGGTGGAGAACACCACTGAGAAGGAGGTGACAGATGAAGACGAA   660 
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Tb...10960      TACGACATCGAGTTAATGGTGGAGAACACCACTGAGAAGGAGGTGACAGATGAAGACGAA   660 
Tb...10950      TACGACATCGAGTTAATGGTGGAGAACACCACTGAGAAGGAGGTGACAGATGAAGACGAA   660 
Tb...10940      TACGACATCGAGTTAATGGTGGAGAACACCACTGAGAAGGAGGTGACAGATGAAGACGAA   660 
Tb...10910      TACGACATCGAGTTAATGGTGGAGAACACCACTGAGAAGGAGGTGACAGATGAAGACGAA   660 
Tb...10920      TACGACATCGAGTTAATGGTGGAGAACACCACTGAGAAGGAGGTGACAGATGAAGACGAA   660 
Tb...10900      TACGACATCGAGTTAATGGTGGAGAACACCACTGAGAAGGAGGTGACAGATGAAGACGAA   660 
Tb...10890      TACGACATCGAGTTAATGGTGGAGAACACCACTGAGAAGGAGGTGACAGATGAAGACGAA   660  
                ************************************************************ 
 
Tb...10930      GACGAAGAGGCCGCCAAAAAGGCTGAGGAAGGTGAGGAGCCAAAGGTGGAAGAGGTGAAG   720 
Tb...10970      GACGAAGAGGCCGCCAAAAAGGCTGAGGAAGGTGAGGAGCCAAAGGTGGAAGAGGTGAAG   720 
Tb...10980      GACGAAGAGGCCGCCAAAAAGGCTGAGGAAGGTGAGGAGCCAAAGGTGGAAGAGGTGAAG   720 
Tb...10960      GACGAAGAGGCCGCCAAAAAGGCTGAGGAAGGTGAGGAGCCAAAGGTGGAAGAGGTGAAG   720 
Tb...10950      GACGAAGAGGCCGCCAAAAAGGCTGAGGAAGGTGAGGAGCCAAAGGTGGAAGAGGTGAAG   720 
Tb...10940      GACGAAGAGGCCGCCAAAAAGGCTGAGGAAGGTGAGGAGCCAAAGGTGGAAGAGGTGAAG   720 
Tb...10910      GACGAAGAGGCCGCCAAAAAGGCTGAGGAAGGTGAGGAGCCAAAGGTGGAAGAGGTGAAG   720 
Tb...10920      GACGAAGAGGCCGCCAAAAAGGCTGAGGAAGGTGAGGAGCCAAAAGTGGAAGAGGTGAAG   720 
Tb...10900      GACGAAGAGGCCGCCAAAAAGGCTGAGGAAGGTGAGGAGCCAAAGGTGGAAGAGGTGAAG   720 
Tb...10890      GACGAAGAGGCCGCCAAAAAGGCTGAGGAAGGTGAGGAGCCAAAGGTGGAAGAGGTGAAG   720  
                ******************************************** *************** 
 
Tb...10930      GACGGCGATGATGCCGATGCCAAGAAAAAGAAAACCAAAAAGGTGAAGGAAGTGAAGCAG   780 
Tb...10970      GACGGTGATGATGCCGATGCCAAGAAAAAGAAAACCAAAAAGGTGAAGGAAGTGAAGCAG   780 
Tb...10980      GACGGCGATGATGCCGATGCCAAGAAAAAGAAAACCAAAAAGGTGAAGGAAGTGAAGCAG   780 
Tb...10960      GACGGCGATGATGCCGATGCCAAGAAAAAGAAAACCAAAAAGGTGAAGGAAGTGAAGCAG   780 
Tb...10950      GACGGCGATGATGCCGATGCCAAGAAAAAGAAAACCAAAAAGGTGAAGGAAGTGAAGCAG   780 
Tb...10940      GACGGCGATGATGCCGATGCCAAGAAAAAGAAAACCAAAAAGGTGAAGGAAGTGAAGCAG   780 
Tb...10910      GACGGCGATGATGCCGATGCCAAGAAAAAGAAAACCAAAAAGGTGAAGGAAGTGAAGCAG   780 
Tb...10920      GACGGCGATGATGCCGATGCCAAGAAAAAGAAAACCAAAAAGGTGAAGGAAGTGAAGCAG   780 
Tb...10900      GACGGCGATGATGCCGATGCCAAGAAAAAGAAAACCAAAAAGGTGAAGGAAGTGAAGCAG   780 
Tb...10890      GACGGCGATGATGCCGATGCCAAGAAAAAGAAAACCAAAAAGGTGAAGGAAGTGAAGCAG   780  
                ***** ****************************************************** 
 
Tb...10930      GAGTTTGTGGTGCAGAACAAGCACAAGCCACTGTGGACGCGCGACCCGAAAGATGTAACA   840 
Tb...10970      GAGTTTGTGGTGCAGAACAAGCACAAGCCACTGTGGACGCGCGACCCGAAAGATGTAACA   840 
Tb...10980      GAGTTTGTGGTGCAGAACAAGCACAAGCCACTGTGGACGCGCGACCCGAAAGATGTAACA   840 
Tb...10960      GAGTTTGTGGTGCAGAACAAGCACAAGCCACTGTGGACGCGCGACCCGAAAGATGTAACA   840 
Tb...10950      GAGTTTGTGGTGCAGAACAAGCACAAGCCACTGTGGACGCGCGACCCGAAAGATGTAACA   840 
Tb...10940      GAGTTTGTGGTGCAGAACAAGCACAAGCCACTGTGGACGCGCGACCCGAAAGATGTAACA   840 
Tb...10910      GAGTTTGTGGTGCAGAACAAGCACAAGCCACTGTGGACGCGCGACCCGAAAGATGTAACA   840 
Tb...10920      GAGTTTGTGGTGCAGAACAAGCACAAGCCACTGTGGACGCGCGACCCGAAAGATGTAACA   840 
Tb...10900      GAGTTTGTGGTGCAGAACAAGCACAAGCCACTGTGGACGCGCGACCCGAAAGATGTAACA   840 
Tb...10890      GAGTTTGTGGTGCAGAACAAGCACAAGCCACTGTGGACGCGCGACCCGAAAGATGTAACA   840  
                ************************************************************ 
 
Tb...10930      AAGGAGGAGTACGCCTCCTTCTACAAGGCCATCTCGAACGACTGGGAAGAGCAGCTGTCT   900 
Tb...10970      AAGGAGGAGTACGCCTCCTTCTACAAGGCCATCTCGAACGACTGGGAAGAGCAGCTGTCT   900 
Tb...10980      AAGGAGGAGTACACCTCCTTCTACAAGGCCATCTCGAACGACTGGGAAGAGCAGCTGTCT   900 
Tb...10960      AAGGAGGAGTACGCCTCCTTCTACAAGGCCATCTCGAACGACTGGGAAGAGCAGCTGTCT   900 
Tb...10950      AAGGAGGAGTACGCCTCCTTCTACAAGGCCATCTCGAACGACTGGGAAGAGCAGCTGTCT   900 
Tb...10940      AAGGAGGAGTACGCCTCCTTCTACAAGGCCATCTCGAACGACTGGGAAGAGCAGCTGTCT   900 
Tb...10910      AAGGAGGAGTACGCCTCCTTCTACAAGGCCATCTCGAACGACTGGGAAGAGCAGCTGTCT   900 
Tb...10920      AAGGAGGAGTACGCCTCCTTCTACAAGGCCATCTCGAACGACTGGGAAGAGCAGCTGTCT   900 
Tb...10900      AAGGAGGAGTACGCCTCCTTCTACAAGGCCATCTCGAACGACTGGGAAGAGCAGCTGTCT   900 
Tb...10890      AAGGAGGAGTACGCCTCCTTCTACAAGGCCATCTCGAACGACTGGGAAGAGCAGCTGTCT   900  
                ************ *********************************************** 
 
Tb...10930      ACGAAGCACTTCTCCGTGGAGGGCCAGCTGGAGTTCCGGGCTATCTTATTTCTCCCGAAG   960 
Tb...10970      ACGAAGCACTTCTCCGTGGAGGGCCAGCTGGAGTTCCGGGCTATCTTATTTCTCCCGAAG   960 
Tb...10980      ACGAAGCACTTCTCCGTGGAGGGCCAGCTGGAGTTCCGGGCTATCTTATTTCTCCCGAAG   960 
Tb...10960      ACGAAGCACTTCTCCGTGGAGGGCCAGCTGGAGTTCCGGGCTATCTTATTTCTCCCGAAG   960 
Tb...10950      ACGAAGCACTTCTCCGTGGAGGGCCAGCTGGAGTTCCGGGCTATCTTATTTCTCCCGAAG   960 
Tb...10940      ACGAAGCACTTCTCCGTGGAGGGCCAGCTGGAGTTCCGGGCTATCTTATTTCTCCCGAAG   960 
Tb...10910      ACGAAGCACTTCTCCGTGGAGGGCCAGCTGGAGTTCCGGGCTATCTTATTTCTCCCGAAG   960 
Tb...10920      ACGAAGCACTTCTCCGTGGAGGGCCAGCTGGAGTTCCGGGCTATCTTATTTCTCCCGAAG   960 
Tb...10900      ACGAAGCACTTCTCCGTGGAGGGCCAGCTGGAGTTCCGGGCTATCTTATTTCTCCCGAAG   960 
Tb...10890      ACGAAGCACTTCTCCGTGGAGGGCCAGCTGGAGTTCCGGGCTATCTTATTTCTCCCGAAG   960  
                ************************************************************ 
 
Tb...10930      CGCGCACCCTTTGACATGTTCGAACCAAACAAGAAGCGCAACAACATCAAGCTATACGTC   1020 
Tb...10970      CGCGCACCCTTTGACATGTTCGAACCAAACAAGAAGCGCAACAACATCAAGCTATACGTC   1020 
Tb...10980      CGCGCACCCTTTGACATGTTCGAACCAAACAAGAAGCGCAACAACATCAAGCTATACGTC   1020 
Tb...10960      CGCGCACCCTTTGACATGTTCGAACCAAACAAGAAGCGCAACAACATCAAGCTATACGTC   1020 
Tb...10950      CGCGCACCCTTTGACATGTTCGAACCAAACAAGAAGCGCAACAACATCAAGCTATACGTC   1020 
Tb...10940      CGCGCACCCTTTGACATGTTCGAACCAAACAAGAAGCGCAACAACATCAAGCTATACGTC   1020 
Tb...10910      CGCGCACCCTTTGACATGTTCGAACCAAACAAGAAGCGCAACAACATCAAGCTATACGTC   1020 
Tb...10920      CGCGCACCCTTTGACATGTTCGAACCAAACAAGAAGCGCAACAACATCAAGCTATACGTC   1020 
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Tb...10900      CGCGCACCCTTTGACATGTTCGAACCAAACAAGAAGCGCAACAACATCAAGCTATACGTC   1020 
Tb...10890      CGCGCACCCTTTGACATGTTCGAACCAAACAAGAAGCGCAACAACATCAAGCTATACGTC   1020  
                ************************************************************ 
 
Tb...10930      CGCCGCGTGTTCATCATGGACAACTGTGAGGACCTGTGCCCCGAGTGGCTCGGCTTCCTG   1080 
Tb...10970      CGCCGCGTGTTCATCATGGACAACTGTGAGGACCTGTGCCCCGAGTGGCTCGGCTTCCTG   1080 
Tb...10980      CGCCGCGTGTTCATCATGGACAACTGTGAGGACCTGTGCCCCGAGTGGCTCGGCTTCCTG   1080 
Tb...10960      CGCCGCGTGTTCATCATGGACAACTGTGAGGACCTGTGCCCCGAGTGGCTCGGCTTCCTG   1080 
Tb...10950      CGCCGCGTGTTCATCATGGACAACTGTGAGGACCTGTGCCCCGAGTGGCTCGGCTTCCTG   1080 
Tb...10940      CGCCGCGTGTTCATCATGGACAACTGTGAGGACCTGTGCCCCGAGTGGCTCGGCTTCCTG   1080 
Tb...10910      CGCCGCGTATTCATCATGGACAACTGTGAGGACCTGTGCCCCGACTGGCTCGGCTTCCTG   1080 
Tb...10920      CGCCGCGTATTCATCATGGACAACTGTGAGGACCTGTGCCCCGAGTGGCTCGGCTTCCTG   1080 
Tb...10900      CGCCGCGTATTCATCATGGACAACTGTGAGGACCTGTGCCCCGAGTGGCTCGGCTTCCTG   1080 
Tb...10890      CGCCGCGTATTCATCATGGACAACTGTGAGGACCTGTGCCCCGAGTGGCTCGGCTTCCTG   1080  
                ******** *********************************** *************** 
 
Tb...10930      CGCGGTGTGGTGGACAGCGAGGACCTGCCACTAAATATCTCCCGTGAGAACCTGCAGCAG   1140 
Tb...10970      CGCGGTGTGGTGGACAGCGAGGACCTGCCACTAAATATCTCCCGTGAGAACCTGCAGCAG   1140 
Tb...10980      CGCGGTGTGGTGGACAGCGAGGACCTGCCACTAAATATCTCCCGTGAGAACCTGCAGCAG   1140 
Tb...10960      CGCGGTGTGGTGGACAGCGAGGACCTGCCACTAAATATCTCCCGTGAGAACCTGCAGCAG   1140 
Tb...10950      CGCGGTGTGGTGGACAGCGAGGACCTGCCACTAAATATCTCCCGTGAGAACCTGCAGCAG   1140 
Tb...10940      CGCGGTGTGGTGGACAGCGAGGACCTGCCACTAAATATCTCCCGTGAGAACCTGCAGCAG   1140 
Tb...10910      CGCGGTGTGGTGGACAGCGAGGACCTGCCACTAAATATCTCCCGTGAGAACCTGCAGCAG   1140 
Tb...10920      CGCGGTGTGGTGGACAGCGAGGACCTGCCACTAAATATCTCCCGTGAGAACCTGCAGCAG   1140 
Tb...10900      CGCGGTGTGGTGGACAGCGAGGACCTGCCACTAAATATCTCCCGTGAGAACCTGCAGCAG   1140 
Tb...10890      CGCGGTGTGGTGGACAGCGAGGACCTGCCACTAAATATCTCCCGTGAGAACCTGCAGCAG   1140 
                ************************************************************ 
 
Tb...10930      AACAAAATCCTCAAGGTGATCCGTAAGAATATTGTGAAGAAGACCCTGGAGCTCTTCGAG   1200 
Tb...10970      AACAAAATCCTCAAGGTGATCCGTAAGAATATTGTGAAGAAGACCCTGGAGCTCTTCGAG   1200 
Tb...10980      AACAAAATCCTCAAGGTGATCCGTAAGAATATTGTGAAGAAGGCCCTGGAGCTCTTCGAG   1200 
Tb...10960      AACAAAATCCTCAAGGTGATCCGTAAGAATATTGTGAAGAAGGCCCTGGAGCTCTTCGAG   1200 
Tb...10950      AACAAAATCCTCAAGGTGATCCGTAAGAATATTGTGAAGAAGGCCCTGGAGCTCTTCGAG   1200 
Tb...10940      AACAAAATCCTCAAGGTGATCCGTAAGAATATTGTGAAGAAGGCCCTGGAGCTCTTCGAG   1200 
Tb...10910      AACAAAATCCTCAAGGTGATCCGTAAGAATATTGTGAAGAAGGCCCTGGAGCTCTTCGAG   1200 
Tb...10920      AACAAAATCCTCAAGGTGATCCGTAAGAATATTGTGAAGAAGGCCCTGGAGCTCTTCGAG   1200 
Tb...10900      AACAAAATCCTCAAGGTGATCCGTAAGAATATTGTGAAGAAGGCCCTGGAGCTCTTCGAG   1200 
Tb...10890      AACAAAATCCTCAAGGTGATCCGTAAGAATATTGTGAAGAAGGCCCTGGAGCTCTTCGAG   1200  
                ****************************************** ***************** 
 
Tb...10930      GAGCTCGCAGAGAACAAGGAGGACTACAAGAAGTTCTACGAACAGTTCAGCAAGAACGTG   1260 
Tb...10970      GAGCTCGCAGAGAACAAGGAGGACTACAAGAAGTTCTACGAACAGTTCAGCAAGAACGTG   1260 
Tb...10980      GAGCTCGCAGAGAACAAGGAGGACTACAAGAAGTTCTACGAACAGTTCAGCAAGAACGTG   1260 
Tb...10960      GAGCTCGCAGAGAACAAGGAGGACTACAAGAAGTTCTACGAACAGTTCAGCAAGAACGTG   1260 
Tb...10950      GAGCTCGCAGAGAACAAGGAGGACTACAAGAAGTTCTACGAACAGTTCAGCAAGAACGTG   1260 
Tb...10940      GAGCTCGCAGAGAACAAGGAGGACTACAAGAAGTTCTACGAACAGTTCAGCAAGAACGTG   1260 
Tb...10910      GAGCTCGCAGAGAACAAGGAGGACTACAAGAAGTTCTACGAACAGTTCAGCAAGAACGTG   1260 
Tb...10920      GAGCTCGCAGAGAACAAGGAGGACTACAAGAAGTTCTACGAACAGTTCAGCAAGAACGTG   1260 
Tb...10900      GAGCTCGCAGAGAACAAGGAGGACTACAAGAAGTTCTACGAACAGTTCAGCAAGAACGTG   1260 
Tb...10890      GAGCTCGCAGAGAACAAGGAGGACTACAAGAAGTTCTACGAACAGTTCAGCAAGAACGTG   1260 
                ************************************************************ 
 
Tb...10930      AAGCTGGGCATCCACGAAGACAGCACAAACCGCAAGAAGCTGATGGAACTGCTGCGCTTC   1320 
Tb...10970      AAGCTGGGCATCCACGAAGACAGCACAAACCGCAAGAAGCTGATGGAACTGCTGCGCTTC   1320 
Tb...10980      AAGCTGGGCATCCACGAAGACAGCACAAACCGCAAGAAGCTGATGGAACTGCTGCGCTTC   1320 
Tb...10960      AAGCTGGGCATCCACGAAGACAGCACAAACCGCAAGAAGCTGATGGAACTGCTGCGCTTC   1320 
Tb...10950      AAGCTGGGCATCCACGAAGACAGCACAAACCGCAAGAAGCTGATGGAACTGCTGCGCTTC   1320 
Tb...10940      AAGCTGGGCATCCACGAAGACAGCACAAACCGCAAGAAGCTGATGGAACTGCTGCGCTTC   1320 
Tb...10910      AAGCTGGGCATCCACGAAGACAGCACAAACCGCAAGAAGCTGATGGAACTGCTGCGCTTC   1320 
Tb...10920      AAGCTGGGCATCCACGAAGACAGCACAAACCGCAAGAAGCTGATGGAACTGCTGCGCTTC   1320 
Tb...10900      AAGCTGGGCATCCACGAAGACAGCACAAACCGCAAGAAGCTGATGGAACTGCTGCGCTTC   1320 
Tb...10890      AAGCTGGGCATCCACGAAGACAGCACAAACCGCAAGAAGCTGATGGAACTGCTGCGCTTC   1320 
                ************************************************************ 
 
Tb...10930      CACAGTTCGGAATCCGGTGAGGAGATGACGACATTGAAGGACTACGTGACACGCATGAAG   1380 
Tb...10970      CACAGTTCGGAATCCGGTGAGGAGATGACGACATTGAAGGACTACGTGACACGCATGAAG   1380 
Tb...10980      CACAGTTCGGAATCCGGTGAGGAGATGACGACATTGAAGGACTACGTGACACGCATGAAG   1380 
Tb...10960      CACAGTTCGGAATCCGGTGAGGAGATGACGACATTGAAGGACTACGTGACACGCATGAAG   1380 
Tb...10950      CACAGTTCGGAATCCGGTGAGGAGATGACGACATTGAAGGACTACGTGACACGCATGAAG   1380 
Tb...10940      CACAGTTCGGAATCCGGTGAGGAGATGACGACATTGAAGGACTACGTGACACGCATGAAG   1380 
Tb...10910      CACAGTTCGGAATCCGGTGAGGAGATGACGACATTGAAGGACTACGTGACACGCATGAAG   1380 
Tb...10920      CACAGTTCGGAATCCGGTGAGGAGATGACGACATTGAAGGACTACGTGACACGCATGAAG   1380 
Tb...10900      CACAGTTCGGAATCCGGTGAGGAGATGACGACATTGAAGGACTACGTGACACGCATGAAG   1380 
Tb...10890      CACAGTTCGGAATCCGGTGAGGAGATGACGACATTGAAGGACTACGTGACACGCATGAAG   1380 
                ************************************************************ 
 
Tb...10930      GATGGTCAGAAGTGCATCTACTATGTGACGGGTGACAGCAAGAAGAAGCTCGAAACGTCT   1440 
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Tb...10970      GATGGTCAGAAGTGCATCTACTATGTGACGGGTGACAGCAAGAAGAAGCTCGAAACGTCT   1440 
Tb...10980      GATGGTCAGAAGTGCATCTACTATGTGACGGGTGACAGCAAGAAGAAGCTCGAAACGTCT   1440 
Tb...10960      GATGGTCAGAAGTGCATCTACTATGTGACGGGTGACAGCAAGAAGAAGCTCGAAACGTCT   1440 
Tb...10950      GATGGTCAGAAGTGCATCTACTATGTGACGGGTGACAGCAAGAAGAAGCTCGAAACGTCT   1440 
Tb...10940      GATGGTCAGAAGTGCATCTACTATGTGACGGGTGACAGCAAGAAGAAGCTCGAAACGTCT   1440 
Tb...10910      GATGGTCAGAAGTGCATCTACTATGTGACGGGTGACAGCAAGAAGAAGCTCGAAACGTCT   1440 
Tb...10920      GATGGTCAGAAGTGCATCTACTATGTGACGGGTGACAGCAAGAAGAAGCTCGAAACGTCT   1440 
Tb...10900      GATGGTCAGAAGTGCATCTACTATGTGACGGGTGACAGCAAGAAGAAGCTCGAAACGTCT   1440 
Tb...10890      GATGGTCAGAAGTGCATCTACTATGTGACGGGTGACAGCAAGAAGAAGCTCGAAACGTCT   1440  
                ************************************************************ 
 
Tb...10930      CCGTTCATCGAGCAGGCGAAGCGCCGCGGCATGGAGGTACTTTTCATGACTGACCCCATC   1500 
Tb...10970      CCGTTCATCGAGCAGGCGAAGCGCCGCGGCATGGAGGTACTTTTCATGACTGACCCCATC   1500 
Tb...10980      CCGTTCATCGAGCAGGCGAAGCGCCGCGGCATGGAGGTACTTTTCATGACTGACCCCATC   1500 
Tb...10960      CCGTTCATCGAGCAGGCGAAGCGCCGCGGCATGGAGGTACTTTTCATGACTGACCCCATC   1500 
Tb...10950      CCGTTCATCGAGCAGGCGAAGCGCCGCGGCATGGAGGTACTTTTCATGACTGACCCCATC   1500 
Tb...10940      CCGTTCATCGAGCAGGCGAAGCGCCGCGGCATGGAGGTACTTTTCATGACTGACCCCATC   1500 
Tb...10910      CCGTTCATCGAGCAGGCGAAGCGCCGCGGCATGGAGGTACTTTTCATGACTGACCCCATC   1500 
Tb...10920      CCGTTCATCGAGCAGGCGAAGCGCCGCGGCATGGAGGTACTTTTCATGACTGACCCCATC   1500 
Tb...10900      CCGTTCATCGAGCAGGCGAAGCGCCGCGGCATGGAGGTACTTTTCATGACTGACCCCATC   1500 
Tb...10890      CCGTTCATCGAGCAGGCGAAGCGCCGCGGCATGGAGGTACTTTTCATGACTGACCCCATC   1500 
                ************************************************************ 
 
Tb...10930      GACGAGTATGTGATGCAGCAAGTGAAGGACTTTGAGGACAAAAAGTTCGCGTGCCTCACA   1560 
Tb...10970      GACGAGTATGTGATGCAGCAAGTGAAGGACTTTGAGGACAAAAAGTTCGCGTGCCTCACA   1560 
Tb...10980      GACGAGTATGTGATGCAGCAAGTGAAGGACTTTGAGGACAAAAAGTTCGCGTGCCTCACA   1560 
Tb...10960      GACGAGTATGTGATGCAGCAAGTGAAGGACTTTGAGGACAAAAAGTTCGCGTGCCTCACA   1560 
Tb...10950      GACGAGTATGTGATGCAGCAAGTGAAGGACTTTGAGGACAAAAAGTTCGCGTGCCTCACA   1560 
Tb...10940      GACGAGTATGTGATGCAGCAAGTGAAGGACTTTGAGGACAAAAAGTTCGCGTGCCTCACA   1560 
Tb...10910      GACGAGTATGTGATGCAGCAAGTGAAGGACTTTGAGGACAAAAAGTTCGCGTGCCTCACA   1560 
Tb...10920      GACGAGTATGTGATGCAGCAAGTGAAGGACTTTGAGGACAAAAAGTTCGCGTGCCTCACA   1560 
Tb...10900      GACGAGTATGTGATGCAGCAAGTGAAGGACTTTGAGGACAAAAAGTTCGCGTGCCTCACA   1560 
Tb...10890      GACGAGTATGTGATGCAGCAAGTGAAGGACTTTGAGGACAAAAAGTTCGCGTGCCTCACA   1560  
                ************************************************************ 
 
Tb...10930      AAGGAGGGTGTACACTTCGAGGAGACGGAGGAAGAGAAGAAACAGCGGGAAGAAGAGAAG   1620 
Tb...10970      AAGGAGGGTGTACACTTCGAGGAGACGGAGGAAGAGAAGAAACAGCGGGAAGAAGAGAAG   1620 
Tb...10980      AAGGAGGGTGTACACTTCGAGGAGACGGAGGAAGAGAAGAAACAGCGGGAAGAAGAGAAG   1620 
Tb...10960      AAGGAGGGTGTACACTTCGAGGAGACGGAGGAAGAGAAGAAACAGCGGGAAGAAGAGAAG   1620 
Tb...10950      AAGGAGGGTGTACACTTCGAGGAGACGGAGGAAGAGAAGAAACAGCGGGAAGAAGAGAAG   1620 
Tb...10940      AAGGAGGGTGTACACTTCGAGGAGACGGAGGAAGAGAAGAAACAGCGGGAAGAAGAGAAG   1620 
Tb...10910      AAGGAGGGTGTACACTTCGAGGAGACGGAGGAAGAGAAGAAACAGCGGGAAGAAGAGAAG   1620 
Tb...10920      AAGGAGGGTGTACACTTCGAGGAGACGGAGGAAGAGAAGAAACAGCGGGAAGAAGAGAAG   1620 
Tb...10900      AAGGAGGGTGTACACTTCGAGGAGACGGAGGAAGAGAAGAAACAGCGGGAAGAAGAGAAG   1620 
Tb...10890      AAGGAGGGTGTACACTTCGAGGAGACGGAGGAAGAGAAGAAACAGCGGGAAGAAGAGAAG   1620 
                ************************************************************ 
 
Tb...10930      GCATCATACGAGCGGCTGTGCAAGGCAATGAAAGAGGTACTTGGTGACAAAGTGGAGAAG   1680 
Tb...10970      GCATCATACGAGCGGCTGTGCAAGGCAATGAAAGAGGTACTTGGTGACAAAGTGGAGAAG   1680 
Tb...10980      GCATCATACGAGCGGCTGTGCAAGGCAATGAAAGAGGTACTTGGTGACAAAGTGGAGAAG   1680 
Tb...10960      GCATCATACGAGCGGCTGTGCAAGGCAATGAAAGAGGTACTTGGTGACAAAGTGGAGAAG   1680 
Tb...10950      GCATCATACGAGCGGCTGTGCAAGGCAATGAAAGAGGTACTTGGTGACAAAGTGGAGAAG   1680 
Tb...10940      GCATCATACGAGCGGCTGTGCAAGGCAATGAAAGAGGTACTTGGTGACAAAGTGGAGAAG   1680 
Tb...10910      GCATCATACGAGCGGCTGTGCAAGGCAATGAAAGAGGTACTTGGTGACAAAGTGGAGAAG   1680 
Tb...10920      GCATCATACGAGCGGCTGTGCAAGGCAATGAAAGAGGTACTTGGTGACAAAGTGGAGAAG   1680 
Tb...10900      GCATCATACGAGCGGCTGTGCAAGGCAATGAAAGAGGTACTTGGTGACAAAGTGGAGAAG   1680 
Tb...10890      GCATCATACGAGCGGCTGTGCAAGGCAATGAAAGAGGTACTTGGTGACAAAGTGGAGAAG   1680  
                ************************************************************ 
 
Tb...10930      GTGGTGGTGTCCGACCGGTTGGCAACATCACCATGCATTCTCGTGACATCAGAGTTCGGG   1740 
Tb...10970      GTGGTGGTGTCCGACCGGTTGGCAACATCACCATGCATTCTCGTGACATCAGAGTTCGGG   1740 
Tb...10980      GTGGTGGTGTCCGACCGGTTGGCAACATCACCATGCATTCTCGTGACATCAGAGTTCGGG   1740 
Tb...10960      GTGGTGGTGTCCGACCGGTTGGCAACATCACCATGCATTCTCGTGACATCAGAGTTCGGG   1740 
Tb...10950      GTGGTGGTGTCCGACCGGTTGGCAACATCACCATGCATTCTCGTGACATCAGAGTTCGGG   1740 
Tb...10940      GTGGTGGTGTCCGACCGGTTGGCAACATCACCATGCATTCTCGTGACATCAGAGTTCGGG   1740 
Tb...10910      GTGGTGGTGTCCGACCGGTTGGCAACATCACCATGCATTCTCGTGACATCAGAGTTCGGG   1740 
Tb...10920      GTGGTGGTGTCCGACCGGTTGGCAACATCACCATGCATTCTCGTGACATCAGAGTTCGGG   1740 
Tb...10900      GTGGTGGTGTCCGACCGGTTGGCAACATCACCATGCATTCTCGTGACATCAGAGTTCGGG   1740 
Tb...10890      GTGGTGGTGTCCGACCGGTTGGCAACATCACCATGCATTCTCGTGACATCAGAGTTCGGG   1740 
                ************************************************************ 
 
Tb...10930      TGGAGTGCACACATGGAACAGATCATGCGCAACCAGGCTCTGCGAGACTCCAGCATGTCT   1800 
Tb...10970      TGGAGTGCACACATGGAACAGATCATGCGCAACCAGGCTCTGCGAGACTCCAGCATGTCT   1800 
Tb...10980      TGGAGTGCACACATGGAACAGATCATGCGCAACCAGGCTCTGCGAGACTCCAGCATGTCT   1800 
Tb...10960      TGGAGTGCACACATGGAACAGATCATGCGCAACCAGGCTCTGCGAGACTCCAGCATGTCT   1800 
Tb...10950      TGGAGTGCACACATGGAACAGATCATGCGCAACCAGGCTCTGCGAGACTCCAGCATGTCT   1800 
Tb...10940      TGGAGTGCACACATGGAACAGATCATGCGCAACCAGGCTCTGCGAGACTCCAGCATGTCT   1800 
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Tb...10910      TGGAGTGCACACATGGAACAGATCATGCGCAACCAGGCTCTGCGAGACTCCAGCATGTCT   1800 
Tb...10920      TGGAGTGCACACATGGAACAGATCATGCGCAACCAGGCTCTGCGAGACTCCAGCATGTCT   1800 
Tb...10900      TGGAGTGCACACATGGAACAGATCATGCGCAACCAGGCTCTGCGAGACTCCAGCATGTCT   1800 
Tb...10890      TGGAGTGCACACATGGAACAGATCATGCGCAACCAGGCTCTGCGAGACTCCAGCATGTCT   1800 
                ************************************************************ 
 
Tb...10930      GCGTACATGATGTCGAAGAAGACCATGGAGATCAACACCACGCACGCCATCGTCAAGGAG   1860 
Tb...10970      GCGTACATGATGTCGAAGAAGACCATGGAGATCAACACCACGCACGCCATCGTCAAGGAG   1860 
Tb...10980      GCGTACATGATGTCGAAGAAGACCATGGAGATCAACACCACGCACGCCATCGTCAAGGAG   1860 
Tb...10960      GCGTACATGATGTCGAAGAAGACCATGGAGATCAACACCACGCACGCCATCGTCAAGGAG   1860 
Tb...10950      GCGTACATGATGTCGAAGAAGACCATGGAGATCAACACCACGCACGCCATCGTCAAGGAG   1860 
Tb...10940      GCGTACATGATGTCGAAGAAGACCATGGAGATCAACACCACGCACGCCATCGTCAAGGAG   1860 
Tb...10910      GCGTACATGATGTCGAAGAAGACCATGGAGATCAACACCACGCACGCCATCGTCAAGGAG   1860 
Tb...10920      GCGTACATGATGTCGAAGAAGACCATGGAGATCAACACCACGCACGCCATCGTCAAGGAG   1860 
Tb...10900      GCGTACATGATGTCGAAGAAGACCATGGAGATCAACACCACGCACGCCATCGTCAAGGAG   1860 
Tb...10890      GCGTACATGATGTCGAAGAAGACCATGGAGATCAACACCACGCACGCCATCGTCAAGGAG   1860 
                ************************************************************ 
 
Tb...10930      CTGAAACGACGCGTGGAGGCCGACGAAAACGACAAGGCCGCCAAGGACCTGATATTCCTC   1920 
Tb...10970      CTGAAACGACGCGTGGAGGCCGACGAAAACGACAAGGCCGCCAAGGACCTGATATTCCTC   1920 
Tb...10980      CTGAAACGACGCGTGGAGGCCGACGAAAACGACAAGGCCGCCAAGGACCTGATATTCCTC   1920 
Tb...10960      CTGAAACGACGCGTGGAGGCCGACGAAAACGACAAGGCCGCCAAGGACCTGATATTCCTC   1920 
Tb...10950      CTGAAACGACGCGTGGAGGCCGACGAAAACGACAAGGCCGCCAAGGACCTGATATTCCTC   1920 
Tb...10940      CTGAAACGACGCGTGGAGGCCGACGAAAACGACAAGGCCGCCAAGGACCTGATATTCCTC   1920 
Tb...10910      CTGAAACGACGCGTGGAGGCCGACGAAAACGACAAGGCCGCCAAGGACCTGATATTCCTC   1920 
Tb...10920      CTGAAACGACGCGTGGAGGCCGACGAAAACGACAAGGCCGCCAAGGACCTGATATTCCTC   1920 
Tb...10900      CTGAAACGACGCGTGGAGGCCGACGAAAACGACAAGGCCGCCAAGGACCTGATATTCCTC   1920 
Tb...10890      CTGAAACGACGCGTGGAGGCCGACGAAAACGACAAGGCCGCCAAGGACCTGATATTCCTC   1920  
                ************************************************************ 
 
Tb...10930      CTCTTCGACACCTCGCTGCTGACATCCGGGTTTACACTTGATGACCCCACGGCATACGCT   1980  
Tb...10970      CTCTTCGACACCTCGCTGCTGACATCCGGGTTTACACTTGATGACCCCACGGCATACGCT   1980 
Tb...10980      CTCTTCGACACCTCGCTGCTGACATCCGGGTTTACACTTGATGACCCCACGGCATACGCT   1980 
Tb...10960      CTCTTCGACACCTCGCTGCTGACATCCGGGTTTACACTTGATGACCCCACGGCATACGCT   1980 
Tb...10950      CTCTTCGACACCTCGCTGCTGACATCCGGGTTTACACTTGATGACCCCACGGCATACGCT   1980 
Tb...10940      CTCTTCGACACCTCGCTGCTGACATCCGGGTTTACACTTGATGACCCCACGGCATACGCT   1980 
Tb...10910      CTCTTCGACACCTCGCTGCTGACATCCGGGTTTACACTTGATGACCCCACGGCATACGCT   1980 
Tb...10920      CTCTTCGACACCTCGCTGCTGACATCCGGGTTTACACTTGATGACCCCACGGCATACGCT   1980 
Tb...10900      CTCTTCGACACCTCGCTGCTGACATCCGGGTTTACACTTGATGACCCCACGGCATACGCT   1980 
Tb...10890      CTCTTCGACACCTCGCTGCTGACATCCGGGTTTACACTTGATGACCCCACGGCATACGCT   1980 
                ************************************************************ 
 
Tb...10930      GACCGTATCCACCGCATGATCAAATTGGGTCTCTCACTCGACGATGATGCGGAAGAGGAG   2040 
Tb...10970      GACCGTATCCACCGCATGATCAAATTGGGTCTCTCACTCGACGATGATGCGGAAGAGGAG   2040 
Tb...10980      GACCGTATCCACCGCATGATCAAATTGGGTCTCTCACTCGACGATGATGCGGAAGAGGAG   2040 
Tb...10960      GACCGTATCCACCGCATGATCAAATTGGGTCTCTCACTCGACGATGATGCGGAAGAGGAG   2040 
Tb...10950      GACCGTATCCACCGCATGATCAAATTGGGTCTCTCACTCGACGATGATGCGGAAGAGGAG   2040 
Tb...10940      GACCGTATCCACCGCATGATCAAATTGGGTCTCTCACTCGACGATGATGCGGAAGAGGAG   2040 
Tb...10910      GACCGTATCCACCGCATGATCAAATTGGGTCTCTCACTCGACGATGATGCGGAAGAGGAG   2040 
Tb...10920      GACCGTATCCACCGCATGATCAAATTGGGTCTCTCACTCGACGATGATGCGGAAGAGGAG   2040 
Tb...10900      GACCGTATCCACCGCATGATCAAATTGGGTCTCTCACTCGACGATGATGCGGAAGAGGAG   2040 
Tb...10890      GACCGTATCCACCGCATGATCAAATTGGGTCTCTCACTCGACGATGATGCGGAAGAGGAG   2040 
                ************************************************************ 
 
Tb...10930      GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG   2100 
Tb...10970      GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG   2100 
Tb...10980      GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG   2100 
Tb...10960      GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG   2100 
Tb...10950      GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG   2100 
Tb...10940      GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG   2100 
Tb...10910      GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG   2100 
Tb...10920      GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG   2100 
Tb...10900      GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG   2100 
Tb...10890      GAAGCGCAGGCACCCGTTGCCGCTGCTGCCGCCAACTCCAGTACTGGTGCGTCGGGTATG   2100 
                ************************************************************ 
 
Tb...10930      GAGGAAGTGGACTGA 2115 
Tb...10970      GAGGAAGTGGACTGA 2115 
Tb...10980      GAGGAAGTGGACTGA 2115 
Tb...10960      GAGGAAGTGGACTGA 2115 
Tb...10950      GAGGAAGTGGACTGA 2115 
Tb...10940      GAGGAAGTGGACTGA 2115 
Tb...10910      GAGGAAGTGGACTGA 2115 
Tb...10920      GAGGAAGTGGACTGA 2115 
Tb...10900      GAGGAAGTGGACTGA 2115 
Tb...10890      GAGGAAGTGGACTGA 2115 
                *************** 
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Tb427tmp.02.0250/Tb11.02.0250 coding sequence (Putative TbTRAP) (69). 




















































































Synthesis of fexinidazole, fexinidazole sulfone, and SCYX-7158, general. 
(Performed by David Meyers, PhD, Department of Pharmacology and Molecular Sciences, JHU)  
For chemical synthesis, all reagents and solvents were used as supplied by commercial sources 
without further purification. Anhydrous solvents were purchased from Aldrich (Sure Seal).  
Reactions involving air and/or moisture-sensitive reagents were carried out under an argon 
atmosphere. For these reactions, glassware was dried under vacuum with a heat gun and then 
filled with argon. Reactions were monitored by thin layer chromatography using Analtech 
chromatography plates (silica gel GHLF, 250 microns). Visualization was performed by UV light 
(254 and 365 nm) and/or by staining with aqueous potassium permanganate solution. Flash 
chromatography was performed using a Grace Reveleris flash purification system and Grace 
silica cartridges (avg. particle size 40 m). 1H (500 MHz) and 13C (126 MHz) NMR spectra of 
compounds were obtained using a Varian spectrometer. 1H NMR spectra acquired in CDCl3 
were referenced to tetramethylsilane (0 ppm), and spectra acquired in d6-DMSO were referenced 
to 2.50 ppm. 13C NMR spectra recorded in CDCl3 were referenced to 77.0 ppm.  Accurate mass 
determinations were recorded by the Mass Spectrometry Laboratory, School of Chemical 
Sciences, University of Illinois. 
 
Synthesis of fexinidazole taken from Samant and Sukhthankar (118). 2-(chloromethyl)-1-
methyl-5-nitro-1H-imidazole was obtained from commercially available (1-methyl-5-nitro-1H-
imidazol-2-yl)methanol as described (119).  Crude product was recrystallized from EtOAc to 
obtain 107 mg of clear, pale yellow crystals in 95% yield.  1H NMR (500 MHz, 
CHLOROFORM-d) 7.96 (s, 1H), 4.69 (s, 2H), 4.05 (s, 3H).  1H NMR is consistent to 
Compound 13 reported by Morrow et al. (119). Fexinidazole was synthesized as described by 
Samant and Sukhthankar (Compound 7a) using Method C.  Crude product was purified using a 0 
to 100% EtOAc/Hex gradient, and the purified product was recrystallized from EtOAc and 
hexanes to provide 1.08 g of yellow crystals in 77% yield.  1H NMR (500 MHz, 
CHLOROFORM-d) 7.97 (s, 1H), 7.22 - 7.31 (m, 2H), 6.91 - 7.01 (m, 2H), 5.19 (s, 2H), 4.06 (s, 
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3H), 2.45 (s, 3H) (Fig. 43A). 13C NMR (126 MHz, CHLOROFORM-d 155.6, 147.4, 139.7, 
131.7, 130.9, 129.6, 115.4, 62.8, 33.8, 17.4 (Fig. 43B).  HRMS (m/z): [MH+] calculated for 
C12H14N3O3S 280.0756, found 280.0758.  
 
Synthesis of the sulfone metabolite of fexinidazole, 1-methyl-2-((4-
(methylsulfonyl)phenoxy)methyl)-5-nitro-1H-imidazole, taken from Fontana et al. (120). 
1H NMR (500 MHz, CHLOROFORM-d)  7.99 (s, 1H), 7.84 - 7.95 (m, J = 8.96 Hz, 2H), 7.14 - 
7.23 (m, J = 8.80 Hz, 2H), 5.30 (s, 2H), 4.07 (s, 3H), 3.03 (s, 3H) (Fig. 43C). 13C NMR (126 MHz, 
CHLOROFORM-d)  161.3, 146.3, 139.8, 133.9, 131.6, 129.8, 115.3, 62.8, 44.7, 33.9 (Fig. 43D).  
HRMS (m/z): [MH+] calculated for C12H14N3O5S 312.0654, found 312.0651. 
 
Synthesis of SCYX-7158 taken from Jacobs et al. (121). 2-(2’-bromophenyl)-6-butyl[1,3,6,2] 
dioxazaborocan was synthesized from 2-bromophenylboronic acid as described (121). Synthesis 
of 4-fluoro-N-(1-hydroxy-3,3-dimethyl-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-2-
(trifluoromethyl)benzamide (SCYX-7158):  To a solution of crude 6-amino-3,3-
dimethylbenzo[c][1,2]oxaborol-1(3H)-ol (0.85 mmoles, 1.0 equiv.) and iPr2NEt (435 ul, 2.55 
mmoles, 3.0 equiv.) in 5 ml anhydrous CH2Cl2 was added 4-fluoro-2-(trifluoromethyl)benzoyl 
chloride (142 L, 0.935, 1.1 equiv.) dropwise at 0 °C.  After addition was complete, the ice water 
cooling bath was removed and the reaction was allowed to warm to rt.  After stirring for 5 h at rt, 
the reaction was diluted with CH2Cl2, and washed with 5% aq. HCl.  The aqueous layer was 
extracted with CH2Cl2 (3 x 10 mL). The organic layers were combined, dried with anhydrous 
MgSO4, and concentrated in vacuo.  Purification by flash chromatography (0 to 100% 
EtOAc/Hex, then 0 to 10% MeOH/EtOAc) provided 85 mg of an impure solid.  A second 
purification using a gradient of 0 to 10% MeOH/CHCl3 provided 38 mg of the desired product.  
1H NMR (500 MHz, DMSO-d6)  10.58 (s, 1H), 9.09 (s, 1H), 8.03 (d, J = 1.73 Hz, 1H), 7.76 - 
7.87 (m, 2H), 7.69 (dt, J = 2.36, 8.57 Hz, 1H), 7.63 (dd, J = 2.04, 8.33 Hz, 1H), 7.39 (d, J = 8.33 






Figure 45. NMR Spectra 
NMR spectra for fexinidazole (A proton, B carbon), and fexinidazole sulfone (C proton, D carbon), 




Figure 46. NMR SCYX-7158 
1
H NMR spectra for SCYX-7158 acquired in d6-DMSO on a Varian spectrometer, created using 
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